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ABSTRACT 
New therapies can improve bone repair as well as preserve bone mass during aging. 
Understanding the mechanisms involved in the regulation of this process is essential for the 
future discovery of treatments that will lead to increased bone formation, improving the life 
quality of a significant part of the population. Forkhead Box OlA (FOXOl) is a transcription 
factor involved in the regulation of diverse cellular responses, such as apoptosis, cell cycle 
arrest and gluconeogenesis. FOXO 1 is active in the nucleus and when phosphorylated by 
protein kinase B, remains inactive in the cytoplasm. 
To identify the relevance of FOXOl during bone and cartilage formation and 
resorption in cells with mesenchymal origin, in vitro studies were carried out with murine 
osteoblastic cell line MC3T3-El, murine chondrocytic cell line ATDC5 and murine 
mesenchymal stem cell line C3H10Tl/2. MC3T3-El cells were treated with ascorbic acid 
and beta glycerophosphate. Increased FOXOl and runt-related transcription factor 2 DNA 
binding activity, alkaline phosphatase activity, formation of mineralized nodules, as well as 
mRNA level of bone markers was induced by mineralization. FOXOl knock down by siRNA 
significantly diminished the increase caused by osteoblast differentiation in all the assays and 
this result was later confirmed by FOXO 1 inhibition through shRNA at mRNA level. Further 
lV 
studies were carried out with MC3T3-El cells; apoptosis and increased FOXOI DNA 
binding activity were induced by a combination of the cytokines interleukin I beta (IL-IP), 
tumor necrosis factor alpha (TNF-a), and interferon gamma (INF-y). Knockdown of FOXOI 
by siRNA significantly reduced cytokine stimulated apoptosis, cleaved caspase-3/7 activity 
and decreased mRNA levels of the pro-apoptotic genes, TNF-a, FAS-associated via death 
domain (FADD), caspase-3, caspase-8 and caspase-9. 
In other experiments A TDC5 cells were treated or not with bone morphogenetic 
protein 2 (BMP2) and stimulated with TNF-a. FOXOI DNA binding activity, apoptosis, 
FOXO I and TNF-a mRNA level showed significant increases after TNF-a stimulation in 
cells that were not treated with BMP2. When FOXO 1 was knocked down by siRNA, 
significant decreases were obtained in the same assays. In A TDC5 cells treated with BMP2, 
FOXOl DNA binding activity, apoptosis and mRNA gene expression of pro-apoptotic, pro-
inflammatory as well as pro-osteoclastogenic genes showed significant increases by TNF-a 
stimulation. On the other hand, FOXOI knock down by siRNA was capable of achieving 
significant decreases in the same assays. These results were confirmed in C3Hl0Tl/2 cells at 
mRNA level, after treatment with BMP2 and TNF-a stimulation as well . When this cell line 
was not treated with BMP2, no response to TNF-a stimulation was found. 
Overall, the results presented in this study demonstrate new insight into the potential 
regulation of bone through the transcription factor FOXO I in cells of mesenchymal origin. 
FOXO 1 was not only involved in the regulation of apoptosis as showed by other studies, but 
also in the regulation of inflammation and osteoclastogenesis during bone formation process. 
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INTRODUCTION 
1- Apoptosis 
Apoptosis, or programmed cell death, is a normal component of development and health of 
multicellular organisms, participating in various biological processes such as development, 
maintenance of tissue homeostasis, and elimination of cells based on physiological and 
pathological conditions (Dash et al., 2007). Apoptotic cells can be easily recognized by 
particular morphological changes including blebbing, shrinkage, chromatin condensation and 
nuclear fragmentation. Apoptotic cells are removed by macrophages that engulf the cells 
causing no inflammatory response (De Nicola et al., 2006). Apoptosis takes place through 
both intrinsic and extrinsic pathways. 
1.1 - Intrinsic Pathway 
The intrinsic pathway is trigged by mitochondrial stress in response to factors such as 
DNA damage and heat shock (Stoka et al., 2006). After receiving the stress signal, the pro-
apoptotic proteins BCL2-associated X protein (BAX) and BH3 interacting domain death 
agonist (BID) from the B-cell CLL/lymphoma family (BCL2) bind to the outer membrane of 
the mitochondria and signal the discharge of its inner content with the assistance of the pro-
apoptotic protein BCL2-antagonist/killer 1 (BAKl). Cytochrome C is then released, and 
forms a complex in the cytoplasm with adenosine triphosphate (ATP) and apoptosis protease 
activating factor (Apaf-1) (Kim et al., 2005). This complex is associated with caspase-9, 
which is an apoptosis initiator. This event leads to the activation of caspase-3; an apoptosis 
effector protein coordinates the implementation of apoptosis. Besides the discharge of 
cytochrome C, the mitochondria also release the apoptosis inducing factor (AIF) (Kim et al., 
2005) and endonuclease G (van Loo et al., 2001) to assist with DNA fragmentation and 
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chromosomal condensation, which are important characteristics of apoptosis. Smac/Diablo 
proteins are also released by the mitochondria to inhibit the inhibitor of apoptosis (IAP) (Du 
et al., 2000). This pathway is regulated by the BCL2 family, which contains pro-apoptotic 
and anti-apoptotic members like BCL2 (Letai et al., 2002). 
1.2 - Extrinsic Pathway 
The extrinsic pathway is characterized by the presence of death receptors. Death 
receptors are cell surface receptors from the tumor necrosis factor (TNF) superfamily that 
activate apoptosis through ligand binding. The best characterized death receptors are TNF 
receptor superfamily member 6 (FAS), which binds to FAS ligand and TNF receptor 1, 
which binds to TNF and lymphotoxin (Dhein et al., 1995; Machleidt et al., 1996). This 
ligand-receptor binding occurs on the surface of the target cell and leads to a direct activation 
of an adaptor protein known as FAS Associated Death Domain (F ADD), or to an indirect 
activation of FADD through TNF-Rl-Associated Death Domain (TRADD) (Ashkenazi and 
Dixit, 1998). F ADD recruits caspase-8, an apoptosis initiator protein to form a death-
inducing signal complex (DISC). Caspase-8 directly activates caspase-3, an apoptotic 
effector protein, in order to start cell death. Caspase-8 is also able to cleave BID protein, and 
in this way, signals the mitochondria to release cytochrome C in the intrinsic pathway, thus 
connecting both apoptotic pathways (Chandra et al., 2004). 
Another ligand involved in apoptosis is tumor necrosis factor (ligand) superfamily, 
member 10 (TRAIL). TRAIL is found in a wide distribution of tissues and like FAS ligand, 
induces apoptosis in various cell lines by binding to two receptors (DR4 and DRS) that 
contain an intracellular death domain (Wiley et al., 1995). TRAIL receptors have the ability 
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to bind in FADD and TRADD and can be repressed by caspase-8 and FADD-like apoptosis 
regulator FLIP (Pan et al., 1997). 
The induction of cell survival was shown to be linked to the activation of nuclear factor-i.:B 
(NF rB), which is responsible for the expression of genes that are essential for cell survival, 
growth, development, oncogenesis, and immune and inflammatory responses (Sha et al., 
1995). Activation ofNF ,~b apparently takes place when TNF-cr binds to TNFRl leading to the 
formation of TRADD, the receptor-interacting protein (RIP), and TNFR-associated factor 2 
(TRAF2), which in turn, results in activation and nuclear translocation of NF 1,B (Thorburn et 
al., 2005). 
1.3 - Reactive Oxygen Species 
Reactive oxygen species (ROS) are bioproducts released by mitochondria during 
oxidative phosphorylation and have an important role in cell signaling. There is evidence that 
ROS are important inducers of apoptosis through an involvement in the induction of FAS and 
FAS ligand and might also be related to the oxidation of the mitochondrial pores, which leads 
to the release of cytochrome C (Garg and Aggarwal, 2002). 
2 - Inflammation 
Inflammation is a multifaceted process, involving various cell types and molecules. It is 
known to be a response of the organism against an injury and is normally associated with 
necrosis. It is characterized by vasodilatation, leukocyte accumulation, enhanced capillary 
permeability and an increased interstitial fluid. This reaction exists in order to defend the 
body against infection and to repair wounded tissue (Pickup, 2004). However, inflammation 
has the potential to cause tissue destruction. Inflammation has a role in the pathogenesis of 
diseases like atherosclerosis, rheumatoid arthritis and gastric cancer (Libby, 2002; Fox and 
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Wang, 2007; Chung et al., 2007). It maybe systemic or local, and normally starts with an 
acute phase which is a rapid, intense and self limiting reaction against an injury stimulus, 
characterized by a change in the level of plasma circulating proteins produced by the 
hepatocytes. This kind of inflammation is recognized by four major signs: redness, swelling, 
heat and pain, and leads to the production of cytokines, including interleukin-6 (IL-6), 
interleukin-1 beta (IL-lP), tumor necrosis factor alpha (TNF-a), interferon gamma (INF-y) 
and transforming growth factor beta (TGF-P) by leukocytes and resident cells at the 
inflammatory site (Kushner, 1993). In regular conditions, the acute inflammatory response is 
normally resolved after a few days (Lawrence, 2007). If inflammation persists, it will be 
altered from the acute to a self-sustaining chronic phase. At this point, other cell types such 
as macrophages, mast cells, T-cells, B-cells, plasma cells, and also eosinophils will be 
involved, and this might lead to local effects with a harmful cost to the organism, such as 
periodontitis for example (Moutsopoulos and Madianos, 2006). 
3 - Forkhead Family of Proteins 
Forkhead box (FOX) proteins are a large family of evolutionarily conserved 
transcriptional regulators with at least 41 genes identified in mammals, characterized by a 
common DNA-binding domain called the forkhead box. Regardless of the highly 
conserved forkhead box, FOX protein regulation and function differ significantly 
between families due to sequence variation outside of the forkhead box. FOXP for 
example is important for the correct immune functioning; FOXC is essential for the 
formation and maturation of the vasculature and FOXA plays an important role in 
organogenesis (Friedman and Kaestner, 2006; Myatt and Lam, 2007). 
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FOXO transcription factors belong to forkhead-O family of proteins, which consist of 
FOXOl, FOXO3a, FOXO4 and FOXO6 in mammals (Van Der Heide et al., 2004). FOXO 
proteins have similar functions and are present in a wide range of cellular and developmental 
processes including regulation of cell death, inhibition of cell cycle progression, modulation 
of the response to oxidative stress (Burgering and Kops, 2002; Birkenkamp and Coffer, 
2003; Burgering and Medema, 2003; Accili and Arden, 2004; Van Der Heide et al., 2004; 
Furukawa-Hibi et al., 2005), DNA repair (Tran et al., 2002), inhibition of adipocyte 
differentiation in fat tissue (Nakae et al., 2003), gluconeogenesis (Schmoll et al., 2000; 
Sekine et al., 2007) and also has a role in speech and language development (Lehmann et al., 
2003). Studies have revealed that FOXOl homozygous null-mutants die before birth due to 
several embryonic defects (Nakae et al., 2002). FOXO 1 is activated by stress and induces the 
expression of genes that decrease reactive oxygen species, thereby improving normal cell 
function (Greer and Brunet, 2005). FOXO is regulated through phosphorylation, acetylation 
and degradation, which affects its capacity to activate gene expression (Accili and Arden, 
2004). Phosphorylation is particularly important for FOXO localization. FOXO is active in 
the nucleus and after phosphorylation by protein kinase B (also known as Akt) in response to 
insulin/growth factors, FOXO is translocated from the nucleus to the cytoplasm, becoming 
inactive. Therefore, FOXO-dependent transcription is inhibited (Datta et al., 1999). PKB is 
dephosphorylated when phosphoinositide 3-kinase (PB) levels are low, and FOXO is 
translocated to the nucleus, which, in tum, activates transcription. PKB phosphorylates 
FOXOl at three different sites: threonine24, serine256, and serine319 . Mutation of these three 
phosphorylation sites, though a substitution for alanine, leads to a constitutively active 
FOXO that remains in the nucleus. Three additional FOXOl sites are not phosphorylated by 
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PKB. Serine322 and serine325 are phosphorylated by casein kinase 1, alpha 1 (CKl), and 
serine329 is phosphorylated by dual-specificity tyrosine-phosphorylated and regulated kinase 
DYRK. This particular site appears to be constitutively phosphorylated, and independent of 
PKB or CKl (Woods and Rena, 2002). In addition to being post-translationally modified by 
phosphorylation, FOXO proteins are also acetylated/deacetylated in order for transcription to 
occur, and these processes are mediated by histone acetyl transferases (HAT) and histone 
deacetylases (HDACs). The most important HATs that interact with FOXO are the calcium 
responsive element binding protein (CBP/p300) and p300/CBP-associated factor (PCAF). 
The HDACs are divided into three classes according to their molecular weight. Both 
acetylases/deacetylases work through the addition or removal of an acetyl group in lysine 
residues and can occur through two different mechanisms, histone or FOXO 
acetylation/deacetylation. Histone acetylation/deacetylation takes place in the nucleosome, 
where acetyl groups break the dense association of DNA and histone, opening the chromatin 
and in this way augmenting the access of transcription factors, and consequently, increasing 
transcription activity. On the other hand, deacetylation removes this acetyl groups and 
present as a result chromatin closing and thus, a diminution of transcription (Sterner and 
Berger, 2000; van der Heide and Smidt, 2005). FOXO 1 acetylation leads to a reduced 
transcription and increased sensivity to PKB phosphorylation at serine256 • In contrast, FOXO 
deacetylation increases FOXO transcription activation (Huang and Tindall, 2007). FOXO is 
degraded through ubiquitination in the cytoplasm (Cohen and Yao, 2004). The 
phosphorylation of FOXOl at serine256 by PKB up-regulates S-phase kinase-associated 
protein 2 (SKP2), which binds to FOXO 1 and induces its ubiquitination and proteosomal 
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degradation. FOXOl is decreased and consequently a diminution in cell cycle and apoptosis 
occur (Huang et al., 2005). 
3.1 - Regulation of Cell Death 
In numerous cell types, activation of the FOXO family leads to apoptosis. Conditions 
that lead to prolonged or high levels of FOXO 1 may be deleterious to a cell by inducing 
apoptosis (Gilley et al., 2003). Some of the FOXO-responsive genes are apoptotic effectors 
such as TNF-a, FAS-ligand and BIM (BIM belongs to the BCL-2 protein family and 
contains a BH3 domain protein that is capable of inducing apoptosis). FOXOl mediates the 
pro-apoptotic effects of TNF-a and TNF-induced pro-apoptotic gene expression (Alikhani et 
al., 2005a). FOXO induces apoptosis through up-regulation of FAS ligand (Brunet et al., 
1999). FOXO induces BIM expression and promotes cell death in sympathetic neurons 
(Modur et al., 2002; Dijkers et al., 2000). One key FOXO target gene is the cyclin-dependent 
kinase inhibitor (CKI) p27KipI, which interacts with cyclin-CDK and inhibits cell cycle 
progression, reducing cell proliferation by cell arrest in G0/G 1, and consequently, increases 
apoptosis (Dijkers et al., 2000). 
3.2- Cell Cycle 
Cell cycle is the process where a eukaryotic cell is replicated. It contains four 
different phases Gl (beginning of DNA synthesis), S (chromosome replication), G2 (mitosis) 
and M (nuclear division), where the activation of each phase depends on the correct 
progression and completion of the previous one (Queralt and Igual, 2003). Cells that have 
stopped dividing reversibly or irreversibility are in a stage called Go phase. Cyclins and 
cyclin-dependent kinases (CDKs) are essential for the cell-cycle progress. They coordinate 
the entry of the cells into the next phase of the cell cycle through phosphorylation. In order 
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to maintain the genomic integrity, cell cycle arrest occurs when DNA is damaged. Cell cycle 
checkpoints are able to detect and delay cell cycle in order to have the damage repaired, or if 
the damage is too extensive, in order to trigger apoptosis. (Furukawa-Hibi et al., 2005; Huang 
et al., 2006). In the presence of DNA damage, CDKs are inhibited, and cells are arrested at 
the G(l), Sor G(2)/M phase of the cell cycle (Huang and Tindall, 2007). FOXO induces cell 
cycle arrest in G1 phase though an increase in the transcription of the cyclin-dependent kinase 
inhibitor p27kipI leading to apoptosis. A lack of p27kipI deeply reduces the antiproliferative 
potential of FOXO (Schmidt et al., 2002). 
3.3 - Gluconeogenesis 
Gluconeogenesis is a vital metabolic pathway that generates glucose from the liver 
and releases it into the bloodstream during prolonged fasting. Two major enzymes regulate it: 
glucose-6-phosphatase, and phosphoenolpyruvate carboxykinase (PEPCK). Glucose-6-
phosphate controls the release of newly synthesized glucose to the bloodstream, while 
PEPCK is the rate-limiting enzyme (Postic et al., 2004). FOXOl stimulates the production of 
glucose in the liver during fasting or starvation in the absence of insulin by up-regulating 
glucose-6-phosphatase and PEPCK, and consequently increasing glucose serum levels 
(Brunet et al., 1999; Nakae et al., 1999). Insulin is an important regulator of gluconeogenesis 
in the liver. It is secreted by the pancreas as a reaction to high levels of glucose in the 
bloodstream, inhibiting gluconeogenesis (Saltiel and Kahn, 2001 ). Once insulin is secreted, it 
triggers FOXO 1 phosphorylation by PKB. Thus FOXO 1 plays an important role in 
regulation of glucose production (Brunet et al., 1999; Nakae et al., 1999). 
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3.4 - Adipocyte Differentiation 
Adipocytes originate from mesenchymal stem cells. Adipose tissue has a critical 
function in energy homeostasis. Adipocytes are able to reserve energy and can drive this 
stored energy to be utilized as substrates for oxidation during an energy deficit (Large et al., 
2004). Adipocytes also secrete factors such as adiponectin, leptin, resistin and cytokines that 
manage energy homeostasis in the body (Ahima and Flier, 2000). FOXOl has an important 
role in adipocyte differentiation; it is able to inhibit adipocyte differentiation through its 
influence on cell cycle progression by the overexpression of cell cycle inhibitors such as p21 
(Sekine et al., 2007). Constitutively active FOXO 1 has been shown to inhibit the 
differentiation of pre-adipocytes into mature adipocytes , while a dominant-negative FOXOl 
reactivates this differentiation pathway (Nakae et al., 2003). 
4 - Mesenchymal Cells 
Mesenchymal cells are multipotent stem cells that have the ability to repair several 
different tissues in the organism (Caplan, 2005a). They are able to differentiate into 
osteoblasts (bone-forming cells), adipocytes (fat cells), chondrocytes (cartilage cells) and 
miocytes (muscle cells) through diverse signals like hormones and growth factors 
(Grigoriadis et al., 1988). An essential signal involved in the progression of each of these 
pathways in mesenchymal cell differentiation is bone morphogenetic protein 2 (BMP2) 
(Wozney et al., 1988; Lee et al., 2000). BMP2 is a secreted signaling molecule of the TGF-P 
superfamily which stimulates the migration and proliferation of mesenchymal progenitors, as 
well as their commitment into the chondrogenic, osteogenic or adipogenic lineage. Low 
concentrations of BMP2 favors adipocyte differentiation and, in contrast, high concentrations 
of BMP2 favors chondrocyte and osteoblast differentiation (Wang et al., 1993; Reddi, 1998). 
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BMP2 was shown to be necessary for the induction of chondrocyte hypertrophy and bone 
formation(Enomoto-Iwamoto et al., 1998; Noel et al., 2004). 
Osteoblasts are uninucleated cells that produce collagenous and noncollagenous bone 
proteins and synthesize a bone organic matrix known as osteoid. In addition, they are 
responsible for the mineralization of the organic matrix (Gerstenfeld et al., 2003). The 
commitment of the differentiation of mesenchymal cells into osteoblasts is an important 
system of skeletal development and bone growth. Runt-related transcription factor 2 
(RUNX2) is an important transcription factor for osteoblast and chondrocyte differentiation 
that determines the lineage of osteoblasts from multipotent mesenchymal cells, inducing 
osteoblast differentiation at the early stages and inhibiting it at the late stage. RUNX2 also 
plays a critical role in chondrocyte proliferation and maturation in order to form 
endochondral bones of appropriate size and shape (Komori, 2002; Yoshida et al., 2004). 
5 - Bone Formation 
Bone formation can occur from two different processes: intramembranous or 
endochondral. The intramembranous bone formation occurs through the differentiation of 
mesenchymal cells into osteoblasts, which synthesize osteoid. This kind of bone formation 
occurs mainly in the neurocranium, viscerocranium and part of the clavicle. On the other 
hand, endochondral bone formation is characterized by the presence of mesenchymal cells in 
the region of the developing bone. These cells are differentiated into proliferative 
chondrocytes, and therefore, initiate the synthesis of cartilage. Later on, the proliferative 
chondrocytes will pass through a second differentiation pathway that will induce their 
conversion into hypertrophic chondrocytes. Endochondral bone formation has an 
orchestrated succession of cellular events that leads to morphological and functional changes 
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in the chondrocytes which will eventually be removed by apoptosis in order to give place to 
ossification. The cranial base, long bones (Howell et al., 1992), and also fracture healing of 
bone develops this way (Brighton and Hunt, 1986; Aizawa et al., 2001 ). 
FOXO 1 is thought to play a role in the differentiation of mesenchymal cells. It has 
been established that the activation of FOXOl obstructs the differentiation of mesenchymal 
cells into fat or muscle cells (Nakae et al., 2003; Armoni et al., 2006). Interestingly, FOXOl 
regulates transcription of the alkaline phosphatase gene, an indicator of osteoblast 
differentiation that contains a forkhead response element in its promoter (Hatta et al., 2002). 
6 - Osteoclasts 
Osteoclasts are multinucleated cells that have originated from hematopoietic 
precursors of the monocyte-macrophage lineage that reside within the bone marrow and are 
responsible for resorption of mineralized cartilage and bone (Chambers et al., 1984; Baron et 
al., 1985). This process is strongly regulated and requires several systemic and local factors, 
such as growth factors, hormones, transcription factors, enzymes, and transporters in order 
for the resorption to take place at the needed levels and at the appropriate skeletal site (Zaidi 
et al., 1993). Tumor necrosis factor (TNF-a), colony stimulating factor-1 (CSF-1) and the 
receptor activator of nuclear factor K~ ligand (RANKL ), interleukin 1 beta (IL-1 ~ ), 
interleukin 6 (IL-6) and interferon gamma (IFN-Y ) are vital for the early steps of the 
pathway that leads to osteoclast differentiation (Balga et al., 2006). 
6.1-RANKL 
RANKL is a constituent of the TNF superfamily expressed by a multiplicity of cell 
types, including osteoblasts, chondrocytes, lynphocytes and macrophages. Its expression is 
augmented in response to cytokines, growth factors and hormones, which stimulate 
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osteoclast differentiation (Teitelbaum, 2007). RANKL is regulated through osteoprotegerin 
(OPG), a decoy RANKL receptor that is also synthesized by osteoblasts and antagonizes 
RANKL-mediated osteoclastogenesis by preventing RANKL from binding to Receptor 
Activator of Nuclear Factor K B (RANK), resulting in inhibition of bone resorption 
(Yamashita et al., 2007). 
6.2 - CSF-1 
CSF-1 1s a cytokine produced by osteoblasts, chondrocytes and macrophages 
(Cecchini et al., 1994; Gerstenfeld et al., 2003; Pixley and Stanley, 2004). CSF-1 induces 
osteoclast differentiation in association with RANKL. It works as a permissive factor by 
giving the survival signal to osteoclasts (Takayanagi, 2005). These functions of CSF-1 might 
be an important factor in the regulation of osteoclastogenesis (Rabello et al., 2006). 
6.3 -TNF-a 
TNF- a is a pro-resorption cytokine produced during the inflammatory process by 
osteoblasts, chondrocytes and macrophages (Gerstenfeld et al., 2003; Robinson et al., 2007). 
It is extremely effective on bone resorption by inhibitiing osteoblast differentiation and 
enhancing osteoclast development. The increase in osteoclast development can occur through 
a stimulation in osteoclastogenesis indepent of RANKL, which was shown in studies with 
RANK deficient mice (Kobayashi et al., 2000; Kim et al., 2006) or through a direct 
stimulation of RANKL and CSF-1 as well as a diminution in the expression of OPG (Iqbal, 
2006). TNF-a contribution to bone loss is observed in periodontitis, orthopedic implant 
loosening and other forms of chronic inflammatory osteolysis (Engebretson et al., 2007; 
Bingham, 2002). 
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6.4 - IL-1J3 
IL-1 p is a cytokine produced during the inflammatory process by osteoblasts, 
chondrocytes, macrophages and lynphocytes that induces the expression of several pro-
inflammatory molecules and hematopoietic cytokines such as IL-6 (Dinarello, 1994). IL-1 
initiates a signaling cascade that activates RANKL or directly activates osteoclastogenesis 
independently of RANKL (Jimi et al., 1999; Hofbauer et al., 1999). The lack of members of 
this pathway leads to osteopetrosis due to a failure in osteoclast differentiation (Engler et al., 
2008). 
6.5 - IL-6 
IL6 is another cytokine produced during the inflammatory process by osteoblasts, 
chondrocytes, macrophages and lynphocytes related to osteoclastogenesis (Dodds et al., 
1994; Akira, 1997; Tokuda et al., 2007). IL-6 effects are related to those ofIL-1 and TNF-a. 
Therefore, IL-6 stimulates osteoclast differentiation by inducing IL-1 discharge and 
mediating TNF-a stimulation (Devlin et al., 1998); it also increases bone resorption by 
increasing osteoclastic progenitors and their differentiation into mature osteoclasts through a 
direct stimulation independent of RANKL or through RANKL stimulation (de la Mata et al., 
1995; Kudo et al., 2003). 
6.6 - Interferon y 
Interferon gamma (IFN-y) is a cytokine synthesized by T lymphocytes, natural killer 
cells, chondrocytes and osteoblasts that is necessary for differentiation, development, and 
function of the immune system. IFN-y induces the release of inflammatory mediators and has 
been shown to affect skeletal tissues (Farrar and Schreiber, 1993; Goldring and Goldring, 
1990). IFN-y can work through two different mechanisms; in osteoclastic progenitor cells, 
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IFN-y prevents bone resorption by inhibiting IL-1~ and RANKL. However, in mature 
osteoclasts, IFN-y stimulates RANKL and TNF-a production, which will promote bone 
resorption (Lorenzo, et al., 2008). 
7 - Chemokines Overview 
Chemokines are small (8-11 kDa) chemotactic cytokine proteins that are secreted by 
different cells in response to growth factors, inflammatory cytokines, and cancer cells 
(Baggiolini, 1998; Moller et al., 2003; Murphy, 2001). Most chemokines have four 
characteristic cysteines, and depending on the motif displayed by the first two cysteines, they 
have been classified into CXC or alpha, CC or beta, C or gamma, and CX3C or delta 
chemokine classes (Rossi and Zlotnik, 2000). In the CXC chemokines, the first two cysteine 
residues are separated by a single amino acid, whereas in the CC chemokines, the first two 
cysteine residues are adjacent to each other (Murphy, 2001; Rossi and Zlotnik, 2000). 
Chemokine receptors are expressed on several cell types including monocytes/macrophages 
(Rossi and Zlotnik, 2000; Zlotnik and Yoshie, 2000). Chemokines have been recognized as 
essential signals for the trafficking of osteoblast and osteoclast precursors, and consequently 
as potential modulators of bone homeostasis (Bendre et al., 2003; Wright et al., 2005). 
The impact of chemokines and their receptors on osteoclasts has been widely studied 
in past years. Recent studies propose that chemokines and their receptors could participate in 
extravasation, migration, and/or survival of osteoclastic cells in vivo (Okamatsu et al., 2004; 
Yu et al., 2004). It has been shown that the chemokine receptor CCR5 and its ligands 
macrophage inflammatory protein 1 alpha (CCL3) and macrophage inflammatory protein 1 
beta (CCL4) stimulate osteoclastogenesis (Abe et al., 2002). 
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7 .1 - Macrophage Inflammatory Proteins 
Macrophage inflammatory proteins 1 alpha and beta are two different chemokines 
also known as CCL3 and CCL4 that induce the production and discharge of other pro-
inflammatory cytokines such IL-1 p, IL-6 and TNF-a. It has been shown that these 
chemokines have a role in hematopoiesis, osteoclast recruitment and osteoclast 
differentiation in vitro (Yang et al., 2006). CCL3 and CCL4 are expressed in bone and 
cartilage and its overexpression leads to an augmented production and differentiation of 
osteoclasts at improper sites and could contribute to pathologic bone loss in vivo, and also 
leads to an increased expression of RANKL, thus increasing bone resorption (Abe et al., 
2002; Roodman and Choi, 2004; Lorenzo et al., 2008). 
RANKL induces the production of CCL2, CCL3, CCL5, and CXCL9 by osteoclasts, 
suggesting an amplification loop composed of autocrine and paracrine signals during 
osteoclast differentiation, which could contribute to bone resorption. In addition to its role in 
osteoclastogenesis, chemokines also affect osteoclast activity through their interactions with 
CXCR4 or CCRl. The CXCR4 ligand, SDF-1/CXCL12, was found to increase MMP-9 
activity in human osteoclasts, resulting in increased bone resorption activity (Grassi et al., 
2004). 
8 - Diabetes 
Diabetes mellitus is a metabolic disease that is predicted to affect over 19 million 
people in the United States (Cowie et al., 2006). Some of its characteristics include 
hyperglycemia, an altered host response, diminished anti-bacterial defenses, prolonged 
inflammation, delayed wound healing and alterations in apoptosis (Goodson and Hunt, 1986; 
Hehenberger et al., 1998; Loots et al., 1998; Trengove et al., 1999; Kane and Greenhalgh, 
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2000; Wetzler et al., 2000; Pierce, 2001; Claxton et al., 2002; Lohmann et al., 2002; Komesu 
et al., 2004; Rai et al., 2005). Diabetes is classified into two major classes, type 1 and type 2 
diabetes. Type 1 diabetes is an autoimmune disease caused by the destruction of pancreatic 
beta cells by autoreactive T cells that lead to the inability of the pancreas to secrete insulin. It 
occurs in approximately ten percent of the diabetic population and normally takes place 
during childhood (Chentoufi et al., 2008). Type 2 diabetes is a group of metabolic disorders 
characterized by insulin resistance, reduced insulin secretion and hyperglycemia. It is mostly 
caused by obesity and primarily occurs in adults (Brunton, 2008). 
8.1 - Consequences 
In diabetes, the dysregulation of metabolic or signaling pathways might lead to 
diabetic complications by distressing important cellular processes. Increased TNF-a is 
associated with a number of diabetic complication including microangiopathy and 
polyneuropathy (Satoh et al., 2003), cardiovascular diseases (Lu et al., 2004), neuropathy 
(Gonzalez-Clemente et al., 2005), retinopathy (Behl et al., 2008), increased inflammation 
associated with infection (Naguib et al., 2004) and periodontitis (Goova et al., 2001; 
Engebretson et al., 2007). 
8.2 - Apoptosis 
Apoptosis has a very significant role in numerous diabetic complications including 
periodontal disease (Graves et al., 2006), nephropathy (Gonzalez-Clemente et al., 2005) and 
cardiovascular diseases (Lu et al., 2004 ). A potential mechanism through which diabetes may 
increase apoptosis is by the excessive production of TNF-a (Taylor, 2001.). This 
overproduction of TNF-a leads to an increase of protein kinase C and oxidative stress. An 
increase in apoptosis may interfere with healing by decreasing the number of cells that 
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participate in new tissue formation (Goodson and Hunt, 1986., Kane and Greenhalgh, 2000; 
Trengove et al., 2000; Pierce, 2001., Claxton et al., 2002; Lohmann et al., 2002). 
8.3 - Inflammation 
Diabetes drives important changes in innate immunity by augmenting PMN and monocyte 
infiltration, enhancing the presence of pro-inflammatory cytokines, and diminishing the 
battle against bacteria (Graves and Kayal, 2008). This increased inflammatory reaction is 
observed in several diseases on the diabetic population, including the early stages of diabetic 
retinopathy for example (Ferris et al., 1999). Increased inflammatory response leads to an 
overproduction of cytokines, which might cause tissue injury in periodontal disease, a delay 
in fracture healing and also in wound healing (Graves and Kayal, 2008). In diabetes, the 
inflammatory process is characterized by the increased plasma concentration of destructive 
mediators such as cytokines and chemokines, caused by indirect effects of hyperglycemia 
(Soop et al., 2002). Over-production of TNF-a is thought to play a role in a number of 
disease processes associated with persistent inflammation and tissue destruction (Ardizzone 
and Bianchi Porro, 2005; et al., 2006; Klimiuk et al., 2004). Increased levels of TNF-a are 
associated with a number of diabetic complications including microangiopathy and 
polyneuropathy (Satoh et al., 2003), cardiovascular diseases (Lu et al., 2004), neuropathy 
(Gonzalez-Clemente et al., 2005), retinopathy (Behl et al., 2008), increased inflammation 
associated with infection (Naguib et al., 2004) and periodontitis (Goova et al., 2001; Graves 
et al., 2006), while NFKB is typically associated with TNF-mediated inflammation (Pessara 
and Koch, 1990). 
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8.4 - Osteopenia 
Osteopenia is associated with decreased bone mineral density and is an important 
complication of type 1 diabetes that maybe caused by the absence of the anabolic effects of 
insulin. Osteopenia is thought to contribute significantly to the increased risk of fractures and 
a delayed fracture healing (Jehle et al., 1998; Tuominen et al., 1999; Kemink et al., 2000; Lu 
et al., 2003; Vestergaard et al., 2005; Leger et al., 2006; Hofbauer et al., 2007). In type 2 
diabetes an increased risk of fractures also occurs regardless the higher bone mass normally 
present due to the augmented weight. As a result, there is an increased risk of falling and 
therefore fracture (Hofbauer et al., 2007). Under some conditions, diabetes has been shown 
to increase osteoclastogenesis and decrease osteoblast differentiation (Krakauer et al., 1995; 
Gough et al., 1997; Jirkovska et al., 2001; Suzuki et al., 2005; Mahamed et al., 2005; Liu et 
al., 2006). Diabetes enhanced osteoclast formation is thought to contribute to diabetic 
osteopenia in adults. Acute Charcot arthropathy is a complication of diabetic neuropathy that 
increases bone fragility and in diabetic fracture healing (Bjorgaas et al., 1999; Kayal et al., 
2007; Naqvi et al., 2008). In diabetic fracture healing and Charcot arthropathy, increased 
osteoclastogenesis has been linked to an increased expression of pro-resorptive factors 
including RANKL, CSF-1 and TNF-a (Kayal et al., 2007; Naqvi et al., 2008). 
8.5 - Delayed Fracture Healing 
Normal fracture repair is dependent upon the coordinated expression of cytokines that 
initially regulate cartilage and bone remodeling (Gerstenfeld et al., 2003). It is facilitated by a 
callus that forms a cartilage matrix, which is resorbed and followed by an endochondral bone 
formation around the fracture site. The callus stabilizes the fracture and allows healing to 
proceed (Gabet et al., 2004). 
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Fractures of the long bones are significantly elevated in diabetics (Davidson and 
Bodey, 1986; Ivers et al., 2001; Nicodemus and Folsom, 2001). Clinical studies have 
reported delayed union or increased healing time in diabetic subjects compared to matched 
controls (Cozen, 1972; Herskind and al, 1992; Loder, 1988). Similar findings of impaired or 
delayed fracture healing have been reported in animal models (Herbsman et al., 1968; Funk 
et al., 2000; Gooch et al., 2000). Normal fracture repair is dependent upon the coordinated 
expression of cytokines that initially regulate cartilage and bone remodeling (Gerstenfeld et 
al., 2003 ). One of the mechanisms by which diabetes may impair fracture healing is by a 
significant increase in RANKL, CSF-1 and TNF-a. This coincides with elevated levels of 
osteoclasts and accelerated degradation of cartilage in diabetic fracture calluses followed by a 
decreased primary bone formation during fracture healing (Kayal et al., 2007). A study by 
Albowi et al (manuscript in preparation) demonstrated that nuclear FOXO 1 protein was 
elevated in diabetic fracture healing in vivo when compared to the matched normoglycemic 
controls. Analysis using laser confocal microscopy confirmed that FOXO 1 nuclear 
translocation was increased in diabetic hypertrophic chondrocytes when compared to the 
matching normoglycemic controls and TNF-a inhibition was shown to reduce FOXO 1 
overexpression in diabetes. 
Animal models have been shown that diabetes could lead to an important increase in 
apoptosis of bone-lining cells made up of periosteal cells and osteoblasts after P. gingivalis 
inoculation in the scalp of type 2 diabetes mice by significantly expanding the time where 
cells were exposed to an increased apoptosis, which was suggested to reduce the ability to 
form new bone due to a repression in the coupling of new bone formation that follows 
resorption (He et al., 2004; Graves et al., 2006). Another study showed that treatment of 
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diabetic mice with a caspase-inhibitor that blocks apoptosis significantly improved the 
formation of new bone in diabetic mice following inoculation of P. gingivalis (Al-Mashat et 
al., 2006). A study using a rat ligature model in type 2 diabetes rats through the placement of 
a ligature containing P. gingivalis around the molar of these animals showed that the 
osteoclast formation and activity as well as the initial bone loss were similar in 
normoglycemic and diabetic rats. However, after the removal of ligatures the diabetic group 
preserved elevated levels of inflammation compared with the normoglycemic group. As a 
result, the diabetic rats continued to lose bone and the amount of new bone produced was 
significantly decreased compared to their normal counterparts, suggesting that the diminished 
osseous repair in diabetic rats may reflect a reduced production of matrix per cell or a 
decreased number of cells capable of producing matrix (Liu et al., 2006). 
A study utilizing animals with type 1 diabetes demonstrated that after the creation of 
craniotomy defects, bone formation was decreased in diabetic animals, suggesting that 
RAGE in particular may contribute to advanced glycation end products (AGE) modulation 
of osteoblast function due to the increased presence of a receptor for advanced glycation end 
products (RAGE) in healing diabetic bone and in osteoblast cultures, speculating that AGE-
RAGE interactions on osteoblastic cells inhibit osteoblast function and contribute to 
diminished bone formation in type 1 diabetes (Santana et al., 2003). Numerous type 1 
diabetes studies have been shown an altered bone remodeling with a decreased new bone 
formation that leads to osteopenia in type 1 diabetes animals. This was shown by a reduction 
in bone mineral density in humans and modifications in the production of new bone in animal 
studies (Levin et al., 1976; Krakauer et al., 1995; Tuominen et al., 1999; Horcajada-Molteni 
et al., 2001 ). The significance of type 1 diabetes on bone formation was shown by a 
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considerable delay in fracture healing (Macey, 1989; Gebauer et al., 2002). The synthesis of 
matrix proteins was also shown to be diminished through a decrease in the production of type 
X collagen during the endochondral bone formation, compared with normal animals (Topping 
et al., 1994). Numerous mechanisms have been proposed for bone abnormalities in diabetics 
including the diminished expression of insulin grown factor 1 or basic fibroblast growth 
factor that may contribute to the reduced production of bone matrix in diabetic bone (Hough 
et al., 1981; Verhaeghe et al., 1992; Verhaeghe et al., 1994; Kawaguchi, et al., 1994). A 
study by Lu et al. showed that the production of immature mesenchymal cells in type 1 
diabetes animals was similar to their normal counterparts in histological analysis. However, 
RUNX2 mRNA levels were reduced in diabetic animals. Thus, diabetic individuals may have 
reduced RUNX2 expression that may direct to a decreased osteoblast differentiation, which 
might reduce the expression of bone-matrix genes and limit the production of new bone (Lu 
et al., 2003). 
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HYPOTHESIS 
This study was undertaken to examine the following hypothesis: 
1- FOXO 1 has an important role in osteoblast differentiation. 
2- FOXOl participates in the regulation of cytokine-induced apoptosis in osteoblasts. 
3- FOXOl is involved in the regulation ofTNF-a-induced apoptosis and TNF-a-
induced inflammation in chondrocytes. 
4- FOXOl has the ability to regulate TNF-induced osteoclastogenesis in BMP2 
stimulated cells (hypertrophic chondrocytes ). 
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MATERIALS AND METHODS 
1 - Cell Culture 
MC3T3-El cells (murine osteoblastic cells) were purchased from ATCC (Rockville, 
MD) and grown in a-MEM (HyClone, South Logan, UT) containing 10% fetal bovine serum 
(FBS) (Atlanta Biologicals, Atlanta, GA), 1 % Penicillin/Streptomycin (Cellgro, Manassas, 
VA) and 1 % non-essential amino acids (Cellgro) at 37° Cina humidified atmosphere of 5% 
CO2 in air. For assays that required mineralization, MC3T3-El cells were also cultured in a-
MEM as described above, but with the addition of 50 µg/ml of ascorbic acid (Fisher Biotech, 
Waltham, MA) and 10 mM of p-glycerophosphate (lnvitrogen, Carlsbad, CA) to the media, 
which was called mineralizing media, and was replaced every other day. 
A TDC5 cells ( chondrogenic mouse embryonic carcinoma cell line) were cultured in a 
1:1 mixture of Dulbecco's modified Eagle's medium and Ham's F-12 medium (Cellgro), 
supplemented with 5% FBS and 1 % Penicillin/Streptomycin at 37° C in a humidified 
atmosphere of 5% CO2 in air. For bone morphogenetic protein 2 (BMP2) stimulation, cells 
were kept in media containing 0.5% FBS and 200 ng/ml of BMP2 (PeproTech, Rocky Hill, 
NJ) for 6 days. 
C3H10Tl/2 cells (murine multipotential stem cells) were purchased from ATCC and 
maintained in Dulbecco's Modification of Eagle's Medium (DMEM), purchased from 
Cellgro, supplemented with 10% FBS and 1 % Penicillin/Streptomycin at 3 7° C in a 
humidified atmosphere of 5% CO2 in air. For BMP2 stimulation, cells were kept in media 
containing 0.5% FBS and 100 ng/ml ofBMP2 for 4 days. 
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2 - Transient Transfection 
MC3T3-El cells were plated in 6 or 24 well plates depending on the assay 24 hours 
prior to the transfection. Cells were transfected at 70% confluence with 5 mM of FOXO 1 
siRNA (target sequence: CCA GCT ATA AAT GGA CAT TTA) or scrambled siRNA 
(Qiagen, Valencia, CA), in the presence of HiPerFect Transfection Reagent (Qiagen), in 
media containing 0.35% FBS. Transfection was performed as follows: for each well in a 6 
well plate, 400 ml of media, 12 µl of HiPerFect Transfection Reagent and either FOXOl 
siRNA or Scrambled siRNA were combined. This mixture was incubated for 15 minutes at 
room temperature in order to allow the transfection complexes to form; 2 minutes prior to the 
end of this incubation, cells were washed with PBS to eliminate the serum present in the 
media. The complexes were then added drop-wise onto the cells, and the plate was swirled to 
ensure a uniform distribution. A few minutes later, another one ml of media was added to the 
cells. Cells were incubated under normal conditions for 24 hours. 
MC3T3-El cells were plated in 6 well plates, and kept in mineralizing media for 2 
days. Cells were then transfected with FOXO 1 siRNA or scrambled siRNA, following the 
protocol described above. 
A TDC5 cells were plated in 6 or 24 well plates depending on the assay 24 hours prior 
to the transfection. Cells were transfected with FOXO 1 siRNA or scrambled siRNA at 70% 
confluence for 24 hours in media containing 0.25% FBS as described in the protocol above. 
ATDC5 cells were stimulated with BMP2 for 6 days, and then plated in 6 or 24 well 
plates depending on the assay 24 hours prior to the transfection. Cells were transfected with 
FOXO 1 siRNA or scrambled siRNA at 70% confluence, in media containing 0.25% FBS for 
24 hours as described in the protocol above. 
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C3Hl0Tl/2 cells were plated in 6 well plates and stimulated with BMP2 for 4 days. 
Cells were transfected with FOXO 1 siRNA or scrambled siRNA at 70% confluence in media 
containing 0.25% FBS for 24 hours as described in the protocol above. 
3 - Lentivirus 
Replication-defective lentiviruses were created usmg a five-plasmid transfection 
procedure expressing five different FOXO 1 siRNA or scrambled siRNA sequences (Open 
Biosystems, Huntsville, AL). 293T cells were transfected using the transfection reagent 
TransIT 293 (Mirus, Madison, WI) having pL VTHM as backbone lentiviral vector (PMID: 
12885912) together with four expression vectors encoding the packaging proteins Gag-Pol, 
Rev, Tat and the G-protein of the vesicular stomatitis virus (VSV-G). Plasmid purification 
was conducted using a transfection-grade maxiprep kit (Marligen, Ijamsville, MD). The 
pLVTHM lentiviral backbone used in the experiments is an optimized self-inactivating 
nonreplicative vector, which contains a cloning site for the siRNA downstream of an Hl 
promoter. Production of virus was carried out by Dr. Dan Faibish. The silencing sequence for 
FOXO 1 was chosen based on the most efficient silence obtained with the plasmid 
transfection as described above (CGGAGGATTGAACCAGTATAA). The scrambled 
sequence was also chosen based on the plasmid transfection 
(TGACGACGAGCGCTCCT ACAG). 
Viral supematants were collected starting 48 hours after transfection, for three 
consecutive collections every 12 hours, pooled and filtered through a 0.45 µm filter. Viral 
supematants were then concentrated in approximately 100 fold by ultracentrifugation in 
Ultra-Clear tubes (Beckman, Fullerton, CA) using an AH-629 rotor (Beckman) for 1.5 hour 
at 16,500 RPM. 
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Virus titering was performed by Dr. Dan Faibish using FG 293T cells infected in the 
presence of 5 µg/ml polybrene (Sigma-Aldrich, St. Louis, MO), with 0.1, 1, 10 µl of viral 
supernatant. The cells were trypsinized after 48 hours and incubated in ice-cold PBS 
supplemented with 2% FBS. GFP expression was measured using fluorescence-activated 
cells sorting (FACS), (FACScan, BD Biosciences), excluding dead cells stained by 
propidium iodide (PI). Data were analyzed using BD Cellquest Pro v5.2 software (BD 
Biosciences, Rockville, MD). All flow cytometric data were acquired using equipment 
maintained by the Boston University Medical Campus Flow Cytometry Core Facility. With 
the use of this protocol titers of about 5 x 108 transducing units/ml were obtained. 
MC3T3-El cells were plated 48 hours prior to transduction in 6-well plates, and kept 
in mineralized media for 2 days. At the time of transduction, media was replaced by media 
supplemented with 5 µg/ml of polybrene (Sigma-Aldrich). Cells were transduced at 40 
different multiplicities of infection (MOI), and incubated for 6 hours with a lentiviral vector. 
After 96 hours, green fluorescence protein (GFP) was checked to observe the efficiency of 
the transduction. Cells were maintained for a total of 14 days in mineralizing media. Total 
RNA was extracted and gene silencing was monitored by real time PCR. 
4 -TNF-a Stimulation 
Depending on the assay, ATDC5 or C3H10Tl/2 cells were starved in 0.25% FBS 
media for 24 hours, and stimulated with 20 ng/ml of TNF-a (PeproTech) for different 
periods of time. For FOXOl DNA binding assay or caspase 3/7 activity, a stimulation of 1 
hour was carried out; for mRNA levels, a stimulation of 6 hours was performed; for TNF-a 
ELISA an overnight stimulation was conducted and for apoptosis assay 24 hours stimulation 
was carried out. 
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5 - Cytokine Stimulation 
MC3T3-El cells were starved in 0.35% FBS media for 24 hours, and then stimulated 
with a combination of 5 ng/ml each of TNF-a, ILl-~ and INF-y (PeproTech) for 48 hours. 
FOXOl DNA binding, apoptosis assay, caspase 3/7 activity and real time PCR were 
performed. 
6 - Cytoplasmic and Nuclear Protein Extraction 
Cytoplasmic and nuclear protein extractions were performed with the NE-PER 
Nuclear and Cytoplasmic Extraction Reagents (Pierce Biotechnology, Rockland, IL) and Halt 
Protease Inhibitor Cocktail (Pierce Biotechnology, Rockland, IL). For the cytoplasmic 
extract, 100 µl of Cytoplasmic Extraction Reagent I was added to the cell pellet to the cells. 1 
µl of Halt Protease Inhibitor Cocktail was added to the cell lysate; it was vigorously vortexed 
for 15 seconds and incubated on ice for 10 minutes. 5.5 µl of Cytoplamic Extraction Reagent 
II was then added to the lysate. The lysate was vortexed again for another 15 seconds, 
incubated on ice for 1 minute, and vortexed another time for 5 seconds. The lysate was then 
centrifuged for 5 minutes in at the highest speed at 4°C. The cytoplasmic extract was 
carefully collected as supernatant, transferred to a pre-chilled tube and frozen immediately in 
-8a° C. For the nuclear extraction, 40 µl of the Nuclear Extraction reagent and 1 µl of the Halt 
Protease Inhibitor Cocktail were added to the pellet and incubated for 40 minutes on ice with 
intermittent vortex of 15 seconds every 10 minutes. The mixture was centrifuged at 
maximum speed in at 4°C for 10 minutes. The supernatant was transferred to a pre-chilled 
tube and frozen immediately in -80° C. The concentrations of both the cytoplasmic and 
nuclear extracts were measured with BCA Protein Assay Kit (Pierce Biotechnology, 
Rockland, IL). 
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7 - Protein Quantification 
The BCA protein assay is a detergent-compatible formulation based on bicinchoninic 
acid (BCA) for the colorimetric detection and quantitation of total protein. This method 
combines the reduction of Cu +z to Cu+ by protein in an alkaline medium (the biuret reaction) 
with the highly sensitive and selective colorimetric detection of the cuprous cation (Cu+) 
using a reagent containing bicinchoninic acid. The purple-colored reaction product of this 
assay is formed by the chelation of two molecules of BCA with one cuprous ion. This water-
soluble complex exhibits a strong absorbance at 550 nm that is nearly linear with increasing 
protein concentrations over a broad working range (20-2,000 µg/ml). The kit contains: BCA 
Reagent A, 1,000 ml, containing sodium carbonate, sodium bicarbonate, bicinchoninic acid 
and sodium tartrate in 0.1 M sodium hydroxide; BCA Reagent B, 25 ml, containing 4% 
cupric sulfate; Albumin Standard Ampoules, 2 mg/ml, containing bovine serum albumin 
(BSA) at 2.0 mg/ml in 0.9% saline and 0.05% sodium azide. Protein concentrations generally 
are determined and reported with reference to standards of a common protein such as bovine 
serum albumin (BSA). A series of dilutions of known concentration are prepared from the 
protein and assayed alongside the unknown( s) before the concentration of each unknown is 
determined based on the standard curve. 
Preparation of the BCA working reagent: working reagent was prepared by mixing 49 
parts of BCA Reagent A with 1 part of BCA Reagent B (50:1, Reagent A: B). In a 96 well 
plate, 200 µl of the working reagent was added to all the wells used. 25 µl of each standard 
or 5 µl of the sample diluted in 20 µl of deionized water were also added to each of the wells . 
The plate was incubated at 37° C for 30 minutes and then read at OD 550 nm. 
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8 - RNA Isolation 
Total RNA was extracted using QIAshredder spin columns (Qiagen, Valencia, CA) 
and the RN easy Mini Kit (Qiagen). The medium was aspirated, 350 µl of RL T Lysis Buffer 
was added in all wells, cells were lysed with the use of a cell lifter (Corning, Coming, NY), 
and transferred into a QIAshredder spin column placed in a 2 ml collection tube. Cells were 
centrifuged for 2 minutes at maximum speed. The QIAshredder spin column was discarded 
and 350 µl of 80% ethanol was added to each sample in order to homogenize the lysate. Each 
sample was then transferred, to an RNeasy spin column placed in a 2 ml tube and centrifuged 
for 15 seconds at 8000 x g; the flow-through was discarded. 700 µl RWl Buffer was added to 
the spin column and centrifuged for 15 seconds at 8000 x g to wash the spin column 
membrane. The column was transferred to a new tube and 500 µl of RPE Buffer was added 
to the spin column followed by a 15 seconds centrifugation at 8000 x g to wash the spin 
column membrane. The flow-through was discarded and another 500 µl of RPE Buffer was 
added for a second time to the spin column membrane, but this time it was centrifuged for 2 
minutes at 8000 x g to dry the membrane. The spin column was placed in a new tube and 
centrifuged at full speed for 1 minute to ensure that the membrane was dry. The column was 
then placed in a new 1.5 ml collection tube. 40 µl of RNase-free water was added directly to 
the spin column membrane and centrifuged for 1 minute at 8000 x g to elute the RNA. 
Finally the elution step was repeated to increase the amount of RNA obtained. Total RNA 
was quantified in a spectrophotometer. 
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9 - Reverse Transcriptase Reaction and Real Time Polymerase Chain Reaction 
After the RNA was extracted and quantified, reverse transcriptase reaction was 
performed using MultiScribe Reverse Transcriptase Kit purchased from Applied Biosystems 
(Foster City, CA), following the manufacture's instructions. 1 µg of RNA was converted into 
cDNA, with the use of 6.61 µl of MgCl, 6 µl of dNTP Mix, 3 µl of 1 OX RT Buffer, 1.5 µl of 
Random Hexamers, 1.89 µl of Reverse Transcriptase, 0.6 µl of RNase Inhibitor Enzyme, and 
RNase free water to bring the volume to 30 µl. The RT PCR cycles used was as follows: 25° 
C for 10 minutes, 37° C for 60 minutes and 95° C for 5 minutes. The cDNA obtained was 
diluted with RNase free water (1-50 dilution), and subjected to real-time PCR to amplify the 
genes of interest in an exponential way. Each reaction was performed as the following: 9 µl 
of the diluted cDNA, 1 µl of a Taqman PCR primer of the gene of interest (Applied 
Biosystems), and 10 µl of Taqman Universal Master Mix (Applied Biosystems) in each well 
used. All reactions were normalized by the housekeeping gene RPL32 (Applied Biosystems). 
The only gene tested that did not have this protocol followed was osteocalcin, due to the 
commercial unavailability of this primer. It was performed with a custom made SYBR Green 
primer with the sequence: 5'-GCAATAAGGTAGTGAACAGACTCC-3' and 
5'-AGCAGGGTTAAGCTCACACTG-3'. It was normalized by B-actin with the sequence: 5'-
GCTCTTTTCCAGCCTTCCTT-3' and 5'-AGGTC TTTACGGATGTCAACG-3 and used 
with a Sybr Green master mix (Applied Biosystems). The cycles used for real time PCR 
were: 50° C for 2 minutes, 95° C for 10 minutes and then for every cycle 95° C for 15 second 
and 60° C for 1 minute. 
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10 - Alkaline Phosphatase Activity 
MC3T3-El cells were plated in 6 well plates and kept in mineralizing media for 2 
days. Cells were then transfected with FOXO 1 siRNA or scrambled siRNA as described 
above and maintained in mineralizing media for a total of 7 and 14 days. The cytoplasmic 
protein extract was obtained as described above, and BCA was performed to normalize the 
samples. Assay was performed by using AP assay reagent A (GenHunter Corporation, 
Nashville, TN), that measures the enzymatic activity of alkaline phosphatase colormetrically. 
50 µl of the AP assay reagent A, 10 µg of cytoplasmic protein extract and enough distilled 
water to adjust the total volume to 100 µl were mixed in an microcentrifuge tube and 
incubated at 37° C. The reaction was stopped with the addition of 100 µl of 0.5 N NaOH 
when a yellow color developed. 800 µl of distilled water was then added to the sample, and 
the sample was read at OD 405 nm in a spectrophotometer. Alkaline phosphatase activity 
was calculated as follows: the OD value obtained from the spectrophotometer was multiplied 
by 54 and divided by the number of minutes that the sample was incubated multiplied by the 
amount of cytoplasmic extract used in microliters. 
11 - Mineralized Nodule Formation 
MC3T3-El cells were plated in 6 well plates and transfected 24 hours later with 
FOXOl siRNA or scrambled siRNA as described above. The media was replaced, and the 
cells were maintained in regular conditions for another week. Cells were then stimulated with 
ascorbic acid only for 2 days and then maintained in mineralizing media for another 2 weeks. 
Mineralized nodules were observed under the microscope, as brown regions, and were also 
observed by naked eye as small white spots. 
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Nodules were stained with Alizarin Red as follows: The media was removed and each 
well was washed with 2 ml of PBS twice. Cells were then fixed with 3 ml of 10% phosphate-
buffered formalin (Electron Microscopy Sciences, Hatfield, PA) for 30 minutes. The fixation 
solution was removed, and the cells were washed twice with deionized water. The plate was 
left open to air dry. 3 ml of Alizarin Red (Ricca Chemical Company, Arlington, TX) was 
added to each well under shaking for 10 minutes. The staining solution was removed, and the 
plate rinsed with deionized water until colorless. A picture of the stained nodules was taken 
with a digital camera and scanned. The number of mineralized nodules formed in each group 
was counted, and the pictures analyzed with the software Image Pro Plus (MediaCybemetics, 
Bethesda, MD). Alizarin red staining was then eluted 3 times with 6.2 ml of 12. lN 
hidrocloridric acid (Fisher Scientific, Pittsburgh, PA), 7.5 grams SDS (Fisher Scientific, 
Pittsburgh, PA) and 150 ml of deionized water. The acid soluble calcium was measured in a 
spectrophotometer at OD 415nm. 
12 - FOXOl DNA Binding Assay 
This assay was performed in all cell types utilized in this study, submitted to different 
treatments. FOXO 1 DNA binding assay (Active Motif, Carlsbad, CA) consists in an ELISA 
kit that contains wells where oligonucleotides containing FOXO 1 consensus sequence 
binding site can bind and be detected through specific antibodies. Assay was performed as 
described bellow following the manufacture's instructions. All the reagents were provided in 
the kit. Nuclear protein was obtained from cells as described above and the BCA assay was 
carried out for sample normalization. 5 µg of nuclear protein was used to perform each assay. 
Reagent Preparation: 
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Complete Binding Buffer was prepared using 0.45 µl Herring Sperm DNA (1 µg/ml) 
and 44.55 µl of Binding Buffer AM6 per well. 
Complete Lysis Buffer was prepared using 0.01 µl of 1 M DTT, 0.12 µl of Protease 
Inhibitor Cocktail and 11.12 µl ofLysis Buffer AMI per well 
lX Wash Buffer was prepared using 2.025 ml of distilled water and 225 µl of lOX 
Wash Buffer AM2 per well. 
lX Antibody Binding Buffer was prepared using Distilled 202.5 µl of distilled water 
and 22.5 µl of 1 OX Ab Binding Buffer AM2 per well. 
In order to start the assay, 40 µl of Complete Binding Buffer was added to each well 
used, followed by the addition of 10 µl of Complete Lysis Buffer, containing 5 µg of nuclear 
protein diluted in it. For competitive binding, 40 µl of Complete Binding Buffer containing 
10 pmol of the wild-type or mutated consensus oligonucleotide was added, followed by the 
addition of 10 µl of Complete Lysis Buffer, containing 5 µg of nuclear protein diluted on it, 
from the group expected to present the highest FOXOl DNA binding activity. An adhesive 
cover was used to seal the plate. The plate was incubated for 1 hour at room temperature with 
mild agitation (100 RPM on a rocking platform). After incubation, each well was washed 3 
times with 200 µl of lX Wash Buffer. 100 µl of diluted FKHR antibody (1 :500 dilution in 
lX Antibody Binding Buffer) was then added to each well being used. The plate was covered 
with the adhesive and incubated for 1 hour at room temperature without agitation. After this 
incubation time, each well was washed 3 times with 200 µl of lX Wash Buffer. 100 µl of 
diluted HRP-conjugated antibody (1: 1000 dilution in 1 X Antibody Binding Buffer) was 
added to all wells, the plate was covered once again with the adhesive, and incubated for 
another hour at room temperature without agitation. During this incubation, the Developing 
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Solution was placed at room temperature. After 1 hour, the wells were washed 4 times with 
200 µl of lX Wash Buffer. 100 µl of room-temperature Developing Solution was then added 
to all wells being used, and they were incubated for about 10 minutes at room temperature 
protected from direct light, until the well developed a blue color. As soon as a blue color 
developed, 100 µl of Stop Solution was added to each well, and the blue color became 
yellow. Absorbance was detected in a plate-reading spectrophotometer (Genious, Tecan, 
Crailsheim, Germany) at 450 nm with a reference wavelength of 620 nm. 
13 - RUNX2 DNA Binding Assay 
This assay was performed in MC3T3-El submitted to mineralization. MC3T3-El 
cells were plated in 6 well plates and kept in mineralizing media for 2 days. Cells were then 
transfected with FOXO 1 siRNA or scrambled siRNA as described above, and were 
maintained in mineralizing media for a total of 7 or 14 days. 
The same nuclear protein used to perform the FOXOl DNA binding assay was used 
in this assay. RUNX2 DNA binding (Active Motif) consists on an ELISA kit that contains 
wells where oligonucleotides containing the RUNX2 consensus sequence binding site can 
bind and be detected through specific antibodies. This assay was performed as described 
bellow following the manufacture's protocol. All the reagents were provided in the kit. 
Nuclear protein was obtained as described above and the BCA assay was carried out for 
sample normalization. 5 µg of nuclear protein was used to perform each assay. Reagent 
Preparation: 
Complete Binding Buffer was prepared using 0.03 µl of 1 M DTT, 0.34 µl Herring 
Sperm DNA and 33.4 µl of Binding Buffer AM2 per well. 
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Complete Lysis Buffer was prepared using 0.02 µl of 1 M DTT, 0.23 µl of Protease 
Inhibitor Cocktail and 22.25 µl of Lysis Buffer AM4 per well. 
lX Wash Buffer was prepared using 2.025 ml of distilled water and 225 µl of lOX 
Wash Buffer AM2 per well. 
lX Antibody Binding Buffer was prepared using 202.5 µl of distilled water and 22.5 
µl of 1 OX Ab Binding Buffer AM2 per well. 
In order to start the assay, 30 µl of Complete Binding Buffer was added to each well used, 
followed by the addition of 20 µl of Complete Lysis Buffer, containing 5 µg of nuclear 
protein diluted in it. For competitive binding, 30 µl of Complete Binding Buffer containing 
20 pmol of the wild-type or mutated consensus oligonucleotide was added, followed by the 
addition of 20 µl of Complete Lysis Buffer, containing 5 µg of nuclear protein diluted on it 
from the group expected to present the highest RUNX2 DNA binding activity. An adhesive 
cover was used to seal the plate. The plate was incubated for 1 hour at room temperature with 
mild agitation (100 RPM on a rocking platform). After incubation, each well was washed 3 
times with 200 µl of lX Wash Buffer. 100 µl of diluted RUNX2 antibody (1:1000 dilution in 
lX Antibody Binding Buffer) was added to each well being used. The plate was covered with 
the adhesive and incubated for 1 hour at room temperature without agitation. After that, the 
wells were washed 3 times with 200 µl of lX Wash Buffer. 100 µl of diluted HRP-
conjugated antibody (1: 1000 dilution in lX Antibody Binding Buffer) was then added to all 
wells, the plate was covered with the adhesive and incubated for another hour at room 
temperature without agitation. During this incubation, the Developing Solution was placed at 
room temperature. After 1 hour, the wells were washed 4 times with 200 µl of lX Wash 
Buffer. 100 µl of room-temperature Developing Solution was then added to all wells being 
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used, and incubated for about 10 minutes at room temperature protected from direct light, 
until the well develops a blue color. As soon as a blue color developed, 100 µl of Stop 
Solution was added to each well, and the blue color turned yellow. Absorbance was detected 
in a plate-reading spectrophotometer (Genious) at 450 nm with a reference wavelength of 
620nm. 
14 - Osteogenesis Focused DNA Microarray 
This assay was performed in MC3T3-El cells. MC3T3-El cells were plated in 6 well 
plates and kept in mineralizing media for 2 days. Cells were then transfected with FOXO 1 
siRNA or scrambled siRNA as described above, and were maintained in mineralizing media 
for a total 14 days. Total RNA was extracted and quantified in a spectrophotometer. An 
Osteogenesis Focused DNA Microarray (Oligo GEArray), purchased from Superarray 
(Frederick, MD) was used to characterize gene expression and was performed by Dr. Yugal 
Behl. 
TrueLabeling-AMP 2.0 (Superarray) was used amplify and label the RNA, 
synthesizing labeled antisense RNA (aRNA), also known as labeled cRNA. All the reagents 
were included in the kit. To obtain cRNA, 3 µg of total RNA was combined with 1 µl of 
TrueLabeling Primer, and enough RNase-Free water to bring the volume to 10 µl. They were 
mixed, briefly centrifuged and incubated at 70° C for 10 min. During this incubation time, 
cDNA Synthesis Master Mix was prepared with the combination of 4 µl of RNase-free water, 
4 µl of 5X cDNA Synthesis Buffer, 1 µl of RNase Inhibitor and 1 µl of cDNA Synthesis 
Enzyme Mix. The reagents were mixed, briefly centrifuged, and placed on ice. The cDNA 
Synthesis Master Mix was combined with the Annealing Mixture mixed, briefly centrifuged 
and incubated at 42° C for 50 minutes followed by 75 °C for 5 minutes then cooled to 37°C. 
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Right before the end of this incubation, the Amplification Master Mix was prepared by the 
combination of 16 µl of 2.5X RNA Polymerase Buffer, 2 µl Biotinylated-UTP, and 2 µl of 
10 mM and RNA Polymerase Enzyme. For the cRNA Synthesis Reaction: 20 µl of the 
Amplification Master Mix was added to each tube containing 20 µl of cDNA Synthesis 
Reaction. They were mixed and briefly centrifuged. This mixture was incubated overnight at 
37° C. 
cRNA Purification: The cRNA obtained was purified using a SuperArray ArrayGrad 
cRNA Cleanup Kit (Superarray). 60 µl of RNase-free water was added to each cRNA 
Synthesis reaction tube. 350 µl of Lysis and Binding Buffer were then added to each sample 
followed by a gentle mix with a pipette. The sample was then loaded onto the center of the 
Spin Column. The column was inserted in a Spin Collection Tube, and centrifuged for 30 
seconds at 8,000 x g. The flow-through was discarded. 600 µI of washing buffer was added 
to the each spin column, and it was centrifuged again for 30 seconds at 8,000 x g. The flow-
through was discarded. Another 200 µl of washing buffer was applied to the spin column, 
and the spin column was centrifuged for 3 minutes at 11,000 x g. The spin column was 
transferred to a new Elution Tube, and 50µ1 of room temperature RNase-free 10 mM Tris pH 
8.0 were added to the spin column. The column was incubated at room temperature for 2 
min, followed by a 1 minute centrifugation at 8000 x g. The cRNA was quantified in a 
spectrophotometer and subsequently kept at -80 °C until the moment that focused microarray 
be performed. 
Focused Microarray: Before staring the focused microarray, the following buffers 
were prepared: 
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Wash buffer: 2 different wash buffers were prepared. For Wash Buffer 1, 10 ml of 20X SSC 
was mixed with 5 ml 20 % SDS and 85 ml double distilled water. For Wash Buffer 2, 0.5 ml 
of 20X SSC was mixed with 2.5 ml 20% SDS, and 97 ml double distilled water. 
IX Buffer F Dilution: 12 ml of 5X Buffer F was diluted in 60 ml of double distilled water 
The Arrays were placed into the Array Multi-Chamber HybPlate using a pair of clean, 
flat forceps with the bar code facing up along the right side of the array. The arrays were 
wetted with 2 ml room temperature, RNase-free water, covered and incubated for 3 minutes. 
The cover was detached, the water was removed and the HybPlate was gently inverted on 
paper towels. The array was pre-hybridized with the addition of 2 ml of pre-warmed 60° C 
GEAhyb Hybridization Solution, was covered again, and gently shacked for a few seconds 
until the membranes started to float in the buffer. After that, the array was incubated without 
agitation for 1 hour at 60 °C. The buffer was then removed, and the HybPlate inverted on 
paper towels. The arrays were carefully transferred to a new HybPlate making sure that no 
hybridization solution was touching the top of the new HybPlate walls. Target Hybridization 
Mix was prepared as follows: For each sample being analyzed, 2 µg of cRNA was combined 
to 2 ml of warm Hybridization Solution, and this mixture was kept at 60 °C. The Target 
Hybridization Mix was carefully added to the hybridization chamber containing an 
Osteogenesis GEArray. The chamber was gently shacked until the Osteogenesis GEArray 
started to float free in the buffer, and then was sealed. Using a fine gauge needle, a small 
puncture was made to vent hole over the middle of chamber. The Osteogenesis GEArray was 
incubated overnight at 60 °C. The Seal was then detached, and the Target Hybridization Mix 
removed. 4 ml of pre-warmed Wash Solution 1 was added to the chamber and gently swirl 
until the membrane was floating. A 60°C incubation was then performed for 5 min, followed 
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by the removal of the buffer and inversion of the HybPlate on paper towels. This wash step 
was repeated another 2 times. 4 ml of pre-warmed Wash Solution 2 was added and the 
HybPlate was gently swirled by hand until the membrane was floating. The HybPlate was 
incubated at 60 °C for 5 minutes, the buffer was then removed and HybPlate inverted on 
paper towels. This wash step was repeated another twice more. 
AP-Streptavidin Incubation and Washes: 2 µl of AP-Streptavidin was diluted into 16 ml 
GEAblocking Solution Q. 2 ml of the diluted AP-Streptavidin was added to the GEArray, 
followed by gently swirl and 10 minutes incubation at room temperature. The buffer was 
then removed, and HybPlate inverted on paper towels. 4 ml of room temperature lX Buffer F 
was added to the chamber, the HybPlate was gently swirl until the membrane is started to 
float, and was then incubated for 5 minutes. The buffer was removed, and the HybPlate 
inverted on paper towels. This wash step was repeated another 3 times. 
Enzyme Buffer Equilibration and CDP-Star Incubation: 4 ml of Buffer G was added to the 
GEArray, and incubated for 1 minute. Buffer G was then removed and 1ml of CDP-Star was 
added and incubated for 5 minutes. CDP-Star was removed, and the HybPlate was inverted 
on paper towels. 
X-ray films were exposed for 5 and 30 minutes. Radiographic images were captured 
utilizing a VersaDoc Imaging system (Bio-Rad, Philadelphia, PA), and the spot intensity 
scanned was analyzed by GeaSuite Array (Superarray). Spot intensities were normalized by 
the housekeeping gene Ribosomal Protein S27a after a 5 minutes exposure of the x-ray. A 
value was considered to be increased when mean and median intensity level was equal to or 
higher then 1. 7 fold in comparison to the corresponding control. On the other hand, a value 
39 
was considered to be decreased when mean and median intensity level was equal to or 
smaller than 0.6 fold in comparison to the corresponding control. 
15 - Chemokines and Receptors Focused PCR Microarray 
This assay was performed in A TDC5 cell BMP2 stimulated (hypertrophic 
chondrocytes). ATDC5 cells were stimulated with BMP2 and plated in 6 well plates. Cells 
were then transfected with FOXOl siRNA or scrambled siRNA as described above. 48 hours 
later, cells were stimulated with TNF-a for 6 hours. Total RNA was extracted using RNeasy 
Mini kit and quantified in a spectrophotometer. Chemokines and Receptors Focused PCR 
Microarray (Superarray) was carried out by Dr. Yugal Behl. 
The first step was RNA purification from protein, organic, and genomic DNA 
contamination. A Genomic DNA Elimination Mixture was performed using 3 µg of RNA, 
mixed with 2 µl of GE (5X gDNA Elimination Buffer), and enough RNase-free water to 
bring the volume to 10 µ1. The contents were gently mixed with a pipette followed by brief 
centrifugation. It was then incubated at 42° C for five minutes, and chilled on ice. RT 
Cocktail was then prepared as follows: 4 µl of BC3 (5X RT Buffer 3) was mixed with 1 µl of 
P2 (Primer and External Control Mix), 2 µl ofRE3 (RT Enzyme Mix 3), and 10 µl ofRNase-
free water. For the First Strand cDNA Synthesis Reaction, 10 µI of RT Cocktail was added to 
a tube containing 10 µl of Genomic DNA Elimination Mixture. The tube was gently mixed 
with a pipette and incubated at 42° C for fifteen minutes, followed by 95° C heating for five 
minutes to stop the reaction. 91 µl of double distilled water was added to the tube with the 
cDNA synthesis reaction. The First Strand cDNA Synthesis Reaction stored overnight at -20° 
C. To perform Real Time PCR, an experimental cocktail was prepared. 1275 µl of 2X 
SuperArray RT2 qPCR Syber Green Master Mix (Superarray) was mixed with 102 µl of the 
40 
Diluted First Strand cDNA Synthesis Reaction and 1173 µl of double distilled water. 25 µl of 
the Experimental Cocktail was added to each well of the PCR Array, using a different pipette 
tip for each well. The PCR Array was then sealed with an optical adhesive film, and placed 
in a real-time thermal cycler. The PCR cycles used were: one cycle of ten minutes at 95° C, 
forty cycles of fifteen seconds at 95° C and to finalize forty cycles of one minute at 60° C. 
The result obtained was exported to a blank Excel spreadsheet to be analyzed by the PCR 
Array Data Analysis Web Portal (Superarray). This website provided the fold change for 
each gene tested, normalized by the housekeeping gene GAPDH and p Value. A value was 
considered to be increased when the mean were equal to or higher than 1. 7 fold in 
comparison to the corresponding control value. On the other hand, a value was considered to 
be decreased when the mean was equal to or smaller than 0.6 fold in comparison to the 
corresponding control value. 
16 - TNF-a ELISA 
This assay was performed in A TDC5 cell BMP2 stimulated (hypertrophic 
chondrocytes ). A TDC5 cells were stimulated with BMP2 and plated in 6 well plates. Cells 
were then transfected with FOXO 1 siRNA or scrambled siRNA as described above. 48 hours 
later, cells were stimulated with TNF-a. TNF-a levels were measured by a quantitative TNF-
a ELISA (RandD Systems, Minneapolis, MN) performed with cytolplasmic protein and 
normalized by BCA as described above. This assay was conducted by Dr. Yugal Behl. The 
kit provided all the reagents, and they were prepared for use as described above: 
Mouse TNF-a Kit Control: Kit Control was reconstituted with 1 ml of deionized 
water. 
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Wash Buffer: for each plate, 25 ml of Wash Buffer Concentrate was mixed with 600 
ml of deionized water. 
Substrate Solution: Color Reagents A and B were mixed together in equal volumes 
fifteen minutes before use, and were protected from light. 
TNF-a Standard: the mouse TNF-a Standard was reconstituted with 2 ml of 
Calibrator Diluent RD5Z, this reconstitution produced a stock solution of 1500 pg/ml. 
A series of 6 dilutions was prepared from the stock solution to obtain a final 
concentration 750 pg/ml, 375 pg/ml, 187.5 pg/ml, 93.8 pg/ml, 46.9 pg/ml and 23.4 pg/ml. 
After the preparation of all the reagents, the assay was performed as follows: 50 µl of Assay 
Diluent RD 1 W was added to each well being used in a 96 well plate coated with monoclonal 
antibody specific for mouse TNF-a. 50 µl of Standard, Control, or sample (25 µg) were than 
added to each well, and mixed by gently tapping the plate frame for 1 minute, covered with 
an adhesive and incubated for 2 hours at room temperature. Each well was aspirated and 
washed 5 times with 400 µl of Wash Buffer. After the last wash, each well was aspirated to 
ensure that all Wash Buffer was removed. 100 µl of mouse TNF-a Conjugate was then 
added to each well. The plate was covered and incubated for 2 hours at room temperature. 
Subsequent to the incubation, another wash/aspiration procedure was performed as described 
above. 100 µl of Substrate Solution was added to each well and incubated for 30 minutes at 
room temperature protected from light. After this incubation, 100 µl of Stop Solution was 
added to each well, and the optical density was determined using a plate-reading 
spectrophotometer (Genious) at 450 nm. 
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17 - Apoptosis Assay 
This assay was performed in MC3T3-El cells, ATDC5 cells stimulated or not with 
BMP2 and C3H10Tl/2 cells stimulated or not with BMP2. Cells were submitted to different 
treatments as described above. 
Apoptosis was measured by the use of a Cell Death Detection ELISA kit (Roche, 
Indianapolis, IN), which detects the amount of histone-associated DNA fragments in mono 
and oligonucleosomes, which are known markers of apoptotic cells. This assay utilizes 
monoclonal antibodies against DNA and histones that leads to the quantification of mono and 
oligonucleosomes in cytoplamic cell lysate. All the reagents were provided in the kit. 100 µl 
of Lysis Buffer was added to each well, and the cells were scraped using a cell scraper 
purchased from BD Falcon (Rockville, MD). The lysate was transferred to a microcentrifuge 
tube and incubated for 30 minutes at room temperature. During this incubation time, an 
immunoreagent was prepared. For each sample, 72 µl of the incubation buffer was mixed 
with 4 µl of Anti-histone-biotin and 4 µl of Anti-DNA monoclonal antibody conjugated with 
peroxidase. After the 30 minutes incubation with the lysis buffer, the samples were 
centrifuged for 10 minutes 200 x g. 30 µl of each sample was removed from the top of the 
supernatant and applied to the center of the each streptavidin-coated well. 80 µl of 
immunoreagent previously made, was added on the top of the sample in each well used. The 
streptavidin-coated strips were covered with an adhesive and incubated on a shaker at 300 
RPM for 2 hours at room temperature. During the 
shaking, a solution containing 2,2' -azino-di-[3-ethylbenzthiazoline sulfonate] (ABTS) was 
prepared by first covering a 15 ml tube with aluminum foil (to avoid light from getting in), 
and Pouring for every 5 ml of the substrate buffer, 1 ABTS tablet. The ABTS solution was 
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then incubated in 4 ° C until about 15 minutes prior to the end of the shaking. After 2 hours 
shaking, the streptavidin-coated strips were rinsed 3 times with 250 µl of incubation buffer. 
100 µl of the ABTS solution was added to each well, and incubated on a plate shaker at 250 
RPM for approximately 10 minutes until a dark green color developed. The samples were 
read in a primary filter of 405 nm and in secondary filter of 492 nm. A BCA assay was 
carried out to normalize the samples. 
18 - Caspase-Glo 3/7 Assay 
This assay was performed in MC3T3-El cells and ATDC5 cells BMP2 stimulated 
(hypertrophic chondrocytes ). Cells were plated in 6 well plates and transfected with FOXO 1 
siRNA or scrambled siRNA. Cells were then submitted to cytokine or TNF-a stimulation as 
described above. This assay was conducted by Dr. Dan Faibish. 
Cytoplasmic protein normalized with BCA was tested for cleaved caspase-3/7 activity 
measured by luminescence with Caspase-Glo TM 3/7 kit from Promega (San Luis Obispo, 
CA), following the manufacture's instructions. This kit contains a luminogenic substrate that 
contains DEVD sequence, which was shown to be selective for caspase 3/7. All the reagents 
were provided with the kit. The assay was performed as follows: Caspase-Glo® 3/7 Buffer 
was transferred to an amber bottle containing Caspase-Glo® 3/7 Substrate; they were mixed 
until the substrate dissolved to form the Caspase-Glo® 3/7 Reagent, and kept in room 
temperature. 25 µg of cytoplasmic protein was added to a luminescent 96 well plate (Dynex, 
Chantilly, VA) followed by the addition of 100 µl of Caspase-Glo® 3/7 Reagent to each well 
used. The wells were gently mixed using a plate shaker, and the plate was covered with and 
adhesive, wrapped in aluminum foil and incubated for thirty minutes at room temperature. 
Luminescence was detected in a plate-reading spectrophotometer (Genious). 
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19 - Reactive Oxygen Species Inhibition 
This assay was performed in A TDC5 cells BMP2 stimulated (hypertrophic 
chondrocytes). Cells were plated in 6 well plates and were pre-incubated with 5 or 10 mM of 
NAC (N-acetyl-L-cysteine) (Sigma-Aldrich) for 2 hours or with 5 or 10 mM of Trolox 
(vitamin E analog) (Calbiochem, Gibbstown, NJ) for 30 minutes, followed by TNF-
a stimulation (20 ng/ml) as described above. FOXOl DNA binding assay and FOXO mRNA 
levels were carried out. 
20 - Caspase-8 and 9 Inhibition 
This assay was performed m A TDC5 cells BMP2 stimulated (hypertrophic 
chondrocytes). Cells were plated in 6 well plates and were incubated with either 50 µM of 
Caspase-8 inhibitor IETD-FMK (RandD Systems), 50 µM of Caspase-9 inhibitor LEHD-
FMK (RandD Systems), or with the mixture of both for 24 hours, combined with 20 ng/ml of 
TNF-a. Apoptosis Assay was performed as described above. 
21 - DNA Isolation 
This assay was performed in ATDC5. DNA isolation was performed with a CHIP 
Express Kit purchased from Active Motif. A TDC5 were plated in 3 15 cm cell culture plates 
24 hours prior to the beginning of the assay. The plates were 70% confluence when the assay 
was performed. The following solutions were prepared for the assay: 
Fixation Solution: 1.62 ml of 37% formaldehyde (Sigma) and 60 ml of minimum 
essential media (Cellgro ). 
Glycine Stop Solution: 3 ml of 1 OX Glycine buffer combined with 3 ml of 1 OX PBS 
and 24 ml of deionized water. 
Scraping Solution: 600 ml of 1 OX PBS combined with 5.4 ml of deionized water. 
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The media was removed from the plates and 20 ml of Fixation Solution was added. 
The plates were gently shacked for 10 minutes at room temperature. The Fixation Solution 
was removed and the plates washed with 10 ml of ice cold 1 X PBS for 5 seconds. 10 ml of 
Glycine Stop Solution was added to stop fixation, and incubated for 5 minutes with gently 
shaking. Glycine Stop Solution was removed by washing the plates with 10 ml of ice cold 1 X 
PBS for 5 seconds. 2 ml of Cell Scraping Solution was added, and the plates were scraped 
with a cell lifter (Coming). The cells were collected into a 15 ml tube and centrifuged for 10 
minutes at 2.500 RPM at 4° C. The cells were then resuspended in 1 ml of ice cold Lysis 
Buffer and incubated on ice for 30 minutes. They were then transfered to an ice cold dounce 
homogenizer (Bellco, Vineland, NJ) with a round bottom and were gently dounced with 
about 20 strokes. The cells were transferred to a microcentrifuge tube and centrifuged for 10 
minutes at 5000 RPM at 4° C to pellet the nuclei. The supernatant was discarded and 1 ml of 
pre-warmed Digestion Buffer was added. The enzymatic reaction was prepared by first 
diluting glycerol in 50% deionized water. A 1: 100 dilution with the enzyme was performed. 
50 ml of the chromatin in digestion buffer was combined with 2.5 ml of the enzyme in 
glycerol and incubated for 15 minutes at 37° C. A group with chromatin and water instead of 
enzyme was also performed and incubated at 3 7° C for the same amount of time that enzyme 
was incubated. The reaction was stopped with 1 ml of EDT A, and incubated on ice for 10 
minutes. The chromatin was then centrifuged at 10. 000 RPM for 10 minutes at 4 ° C, and then 
transferred to a new tube.150 ml of deionized water, 8 ml of NaCl and 1 ml of RNAse-A 
were added to each tube used, vortex and incubated overnight at 65° C. After that, samples 
were briefly centrifuged and 10 ml of Proteinase-K was added. 1.5 hours incubation was 
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carried out at 45° C. Half of the DNA was run directly in an agarose gel; the other half was 
first purified to obtain clear bands. 
22 - DNA Purification 
DNA was purified using a QIAquick PCR Purification Kit purchased from Qiagen. 5 
volumes of Binding Buffer was added to 1 volume of sample and mixed. A MinElute column 
was placed in a 2 ml collection tube, and the sample was applied on it. The column was 
centrifuged for 1 minute and the flow-through was discarded. The MinElute column was 
placed back into the same tube, washed with 750 µl of Wash Buffer and centrifuged for 1 
minute. The flow-through was discarded; the MinElute column was placed back into the 
same tube and centrifuged for an additional 1 minute at maximum speed. The MinElute 
column was then placed in a clean 1.5 ml microcentrifuge tube and the DNA was eluted with 
50 µl Elution Buffer through a 1 minute centrifugation. 10 µl of the purified DNA was 
analyzed in an agarose gel side by side with the unpurified DNA with the addition of 2 µl of 
loading dye. 
23 - Statistical Analysis 
Statistical analysis was assessed by One Way ANOV A with Sheffe's post-hoc for 
comparisons between multiple groups and students t-test test for comparisons between two 
groups, with significance set at P<0.05. The data are presented as percent maximum and 
expressed as means ± standard errors (SEMs). In all assays, three separate independent 
experiments were carried out. For microarrays three sets of cells were stimulated, RNA was 
combined and three sets of microarrays were carried out separately. 
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RESULTS 
1 - FOXOl time course study in mineralizing cultures. 
To observe the extent of the effects of FOXOl siRNA in mineralizing cultures, 
MC3T3-El cells were cultured in media containing 50 µg/ml of ascorbic acid and 10 mM of 
P-glycerophosphate (mineralizing media) for 28 days. Two days after this treatment was 
initiated, a transient transfection with FOXO 1 siRNA and scrambled siRNA was conducted. 
Total RNA was obtained after 4, 7, 14, 21 and 28 days of culture in mineralizing media. 
FOXOl mRNA levels were measured by real time PCR (Fig. 1). The results indicate an 
increase of 1.2 fold on day 4 (P>0.05), 1.5 fold on day 7 (P>0.05), 2 fold on day 14 (P<0.05), 
1.8 fold on day 21 (P<0.05) and 1.6 fold on day 28 (P>0.05) in FOXOl compared to cells not 
maintained in mineralizing media harvested prior to transfection. A reduction of 
approximately 50% in FOXO 1 with FOXO 1 siRNA was obtained on days 4, 7 and 14 
compared to scrambled siRNA (P<0.05). On days 21 and 28, a decrease of 37% and 17% 
respectively in FOXO 1 was also found compared to scrambled siRNA (P>0.05). Based on 
the results obtained in this time course study, day 7 and day 14 were chosen as time points 
for the other assay performed in the mineralizing cultures. 
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Figure 1: Silencing by FOXOl siRNA is more effective between days 4 and 14 in 
mineralizing cultures. 
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Figure 1: Silencing by FOXOl siRNA is more effective between days 4 and 14 in 
mineralizing cultures. MC3T3-El cells were incubated in mineralizing culture media and 
transfected with either FOXO 1 specific or scrambled siRNA as described in Materials and 
Methods. After 4, 7, 14, 21 and 28 days total RNA was isolated. (a) Analysis of FOXOl 
mRNA levels was performed by real time PCR and normalized to ribosomal protein L32 as 
described in Materials and Methods. The data presented are the result of one experiment 
perfumed in triplicates ± SEM and are shown as percent of maximum stimulation. Asterisks 
indicate significantly increased values compared to day zero and double asterisks indicate 
significant reduction compared to cells treated with scrambled siRNA (P < 0.05). 
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2 - The role of FOXOl in osteoblast differentiation. 
To explore the role of FOXOl in osteoblast differentiation , MC3T3-El cells were 
cultured in media containing 50 µg/ml of ascorbic acid and 10 mM of p-glycerophosphate 
(mineralizing media) for 14 days. Two days after this treatment was initiated , a transient 
transfection with FOXO 1 siRNA and scrambled siRNA was conducted. Nuclear protein and 
total RNA were obtained after 7 and 14 days of culture in mineralizing media . FOXOl DNA 
binding assay and FOXO 1 mRNA levels were assessed (Fig. 2). The results indicate that 
after 7 and 14 days of culture , FOXOl DNA binding assay increased 1.7 fold (P>0.05) on 
day 7 and 2.5 fold (P<0.05) on day 14 compared to cells not maintained in mineralizing 
media harvested prior to transfection. When FOXO 1 was knocked down by siRNA, a down-
regulation of 38% (P>0.05) on day 7 and 48% (P<0.05) on day 14 was found in FOXOl 
DNA binding compared to scrambled siRNA (Fig. 2a). FOXOl mRNA levels were 1.2 fold 
(P>0.05) and 2.2 fold (P<0.05) increased after 7 and 14 days of culture compared to cells not 
maintained in mineralizing media harvested prior to transfection. FOXO 1 knock down 
reduced FOXO 1 mRNA levels by 41 % (P>0.05) and 50% (P<0.05) compared to scrambled 
siRNA after 7 and 14 days culture (Fig 2b ). 
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Figure 2: FOXOl siRNA reduced FOXOl DNA binding and FOXOl mRNA levels in 
mineralizing cultures. 
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Figure 2: FOXOl siRNA reduced FOXOl DNA binding and FOXOl mRNA levels in 
mineralizing cultures. MC3T3-El cells were incubated in mineralizing culture media and 
transfected with either FOXOl specific or scrambled siRNA as described in Materials and 
Methods. After 7 and 14 days nuclear protein and total RNA were isolated. (a) FOXOl DNA 
binding assay was carried out as described in Materials and Methods. Specificity of the assay 
was confirmed by reduced detection of FOXO 1 in the sample treated with competitive 
oligonucleotides (comp.) and absence of competition with non competitive oligonucleotides 
(non-comp.). (b) Analysis of FOXOl mRNA levels was performed by real time PCR and 
normalized to ribosomal protein L32 as described in Materials and Methods. The data 
presented are the mean of three independent experiments ± SEM and are shown as percent of 
maximum stimulation. Asterisks indicate significantly increased values compared to day zero 
and double asterisks indicate significant reduction compared to cells treated with scrambled 
siRNA (P < 0.05). 
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3 - FOXOl is involved in the regulation of important bone markers during osteoblast 
differentiation at mRNA levels. 
To find out if important bone markers were affected by FOXOl during osteoblast 
differentiation, MC3T3-El cells were cultured in media containing 50 µg/ml of ascorbic acid 
and 10 mM of p-glycerophosphate (mineralizing media) for 14 days. Two days after this 
treatment was initiated, a transient transfection with FOXO 1 siRNA and scrambled siRNA 
was conducted. Total RNA was extracted after 7 and 14 days of culture in mineralizing 
media. mRNA levels of RUNX2, osteocalcin, type I collagen, MMP 13 and SMAD5 were 
tested. MC3T3-El cells in mineralizing cultures up-regulated RUNX2 mRNA levels by 2.5 
fold (P<0.05) on day 7 and 7 fold (P<0.05) on day 14 compared to cells not maintained in 
mineralizing media harvested prior to transfection. When FOXO 1 was knocked down, a 
down-regulation of 22% (P>0.05) on RUNX2 was found on day 7 and 55% (P<0.05) on day 
14 compared to scrambled siRNA (Fig. 3a). Osteocalcin was 3 fold (P>0.05) and 50 fold 
(P<0.05) increased compared to cells not maintained in mineralizing media harvested prior to 
transfection after 7 and 14 days of culture in mineralizing media, but once FOXO 1 was 
knocked down, a reduction of 26% (P>0.05) and 40% (P<0.05) in osteocalcin was found 
compared to scrambled siRNA after 7 and 14 days of culture in mineralizing media (Fig. 3b ). 
Type I collagen was 1.7 fold (P>0.05) and 3.5 fold (P<0.05) increased after 7 and 14 days of 
culture in mineralizing media compared to cells not maintained in mineralizing media 
harvested prior to transfection. When FOXO 1 was knocked down, a reduction of 50% 
(P>0.05) and 40% (P<0.05) was obtained in type I collagen after 7 and 14 days of culture in 
mineralizing media compared to scrambled siRNA (Fig. 3c). MMP13 did not express any 
changes after 7 days of culture in mineralizing media compared to cells not maintained in 
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mineralizing media harvested prior to transfection. However, a 4 7 fold (P<0.05) increase in 
MMP13 was obtained after 14 days of culture in mineralizing media compared to cells not 
maintained in mineralizing media harvested prior to transfection. (Fig. 3d). FOXOl knock 
down decreased the expression of MMP13 by 50% (P>0.05) and 43% (P<0.05) after 7 and 
14 days of culture in mineralizing media compared to scrambled siRNA. SMAD5 was 1. 7 
fold (P<0.05) increased on day 7 and 2.6 fold (P<0.05) increased on day 14 compared to cells 
not maintained in mineralizing media harvested prior to transfection. When FOXO 1 was 
knocked down, no changes on SMAD5 were found on day 7 compared to scramble siRNA. 
However, a reduction of 45% (P<0.05) in SMAD5 on day 14 was obtained compared to 
scrambled siRNA (Fig. 3e ). 
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Figure 3: FOXOl siRNA reduced mRNA levels of RUNX2, osteocalcin, type I collagen, 
MMP13 and SMAD5 in MCET3-El cells cultured in mineralizing media. 
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Figure 3: FOXOl siRNA reduced mRNA levels of RUNX2, osteocalcin, type I collagen, 
MMP13 and SMAD5 in MCET3-El cells cultured in mineralizing media. MC3T3-El 
cells were cultured under mineralizing conditions and transfected with either FOXO 1 
specific or scrambled siRNA as described in Materials and Methods. After 7 and 14 days, 
total RNA was extracted; mRNA levels were measured by real time PCR and normalized to 
ribosomal protein L32 as described in Materials and Methods. (a) RUNX2 mRNA levels. (b) 
Osteocalcin mRNA levels. (c) Type I collagen mRNA levels. (d) MMP13 mRNA levels. (e) 
SMAD5 mRNA levels. The data presented are the mean of three independent experiments ± 
SEM and are shown as percent of maximum stimulation. Asterisks indicate significantly 
increased values compared to day zero and double asterisks indicate significant reduction 
compared to cells treated with scrambled siRNA (P < 0.05). 
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4 - FOXOl regulates osteoblast differentiation-induced gene expression. 
A focused osteogenesis microarray was performed to discover the role of FOXO 1 in 
oseoblast differentiation in a more comprehensive way. MC3T3-El cells were cultured in 
media containing 50 µg/ml of ascorbic acid and 10 mM of p-glycerophosphate (mineralizing 
media) for 14 days. Two days after this treatment was initiated, a transient transfection with 
FOXOl siRNA and scrambled siRNA was conducted. Total RNA was extracted after 14 
days of culture in mineralizing media and a microarray was carried out (Table 1 ). The results 
showed that 80% of the genes present in the array were up-regulated by the mineralized 
cultures compared to cells not maintained in mineralizing media harvested prior to 
transfection and 67% of the genes were down-regulated by FOXO 1 knock down when 
compared to scrambled siRNA. RUNX-2, BMP-2 and alkaline phosphatase (AKP-2) which 
are well known to be elevated during mineralization in bone formation process were up-
regulated by 2.56 fold, 2.89 fold and 2.62 fold compared to day zero. The same genes were 
down regulated by FOXO 1 knock down by 0.44 fold, 0.32 fold and 0.50 fold respectively 
after compared to scrambled siRNA. Overall, the microarray confirmed that FOXOl plays an 
important role in the regulation of genes that affect osteoblast differentiation and bone 
formation. 
Selected genes from the microarray were confirmed by real time PCR (Fig. 4). For 
each gene, mineralized cultures had similar effects independently of the assay, being 
increased by at least 1. 7 fold in both microarray and real time PCR (Fig. 4a). When FOXO 1 
was knocked down, a minimum of 0.6 fold change was found independently assay as well 
(Fig. 4b ). Therefore the microarray results were confirmed by real time PCR. 
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Table 1 - Focused osteogenic microarray 
Increased by Mineralization Decreased by FOX01 Knock Down (fold change) {fold change} 
Gene Standard Standard 
Name Mean Median Error Mean Median Error 
Mmp13 5.40 4.99 1.88 0.41 0.49 0.12 
ltgav 3.88 3.92 0.79 0.39 0.45 0.07 
lbsp 3.78 3.75 0.45 0.92 0.82 0.12 
Fgf2 3.77 4.10 0.52 0.41 0.42 0.02 
Col11a1 3.59 2.99 1.05 0.48 0.51 0.05 
Gdf10 3.57 3.44 0.92 0.52 0.58 0.09 
Col12a1 3.27 3.28 0.39 0.35 0.35 0.00 
Den 3.23 3.13 0.21 0.62 0.63 0.15 
Col18a1 3.15 2.86 0.61 0.44 0.45 0.05 
ltga3 3.13 3.02 0.53 0.42 0.46 0.07 
Phex 3.10 3.08 0.51 0.41 0.49 0.10 
Fgf1 3.09 3.17 0.32 0.41 0.41 0.00 
Msx1 3.06 2.49 0.63 0.41 0.39 0.03 
Col4a4 2.99 2.82 0.35 0.37 0.38 0.03 
Col19a1 2.93 2.72 0.36 0.39 0.39 0.04 
Bmp6 2.91 2.92 0.22 0.37 0.35 0.03 
Bmp8b 2.90 2.95 0.27 0.34 0.33 0.01 
Mmp8 2.89 3.14 0.28 0.41 0.44 0.04 
Bmp2 2.89 2.78 0.14 0.32 0.34 0.02 
Ambn 2.84 2.93 0.31 0.41 0.37 0.05 
Csf2 2.83 2.96 0.40 0.43 0.45 0.04 
Bmpr1a 2.82 2.73 0.28 0.37 0.39 0.03 
Cd36 2.82 2.86 0.24 0.38 0.38 0.03 
Fgfr1 2.81 2.74 0.15 0.42 0.37 0.07 
Comp 2.81 2.61 0.31 0.40 0.40 0.01 
Col2a1 2.80 2.44 0.87 0.53 0.54 0.10 
Col4a3 2.80 2.89 0.15 0.42 0.43 0.06 
Bmp5 2.76 2.86 0.10 0.35 0.37 0.01 
Col14a1 2.75 2.84 0.14 0.38 0.36 0.06 
Dmp1 2.74 2.41 0.38 0.53 0.46 0.08 
Caler 2.73 2.85 0.15 0.36 0.38 0.02 
Bmp7 2.70 2.67 0.17 0.40 0.39 0.03 
ltgam 2.69 2.42 0.71 0.40 0.41 0.01 
Fgf3 2.69 2.71 0.12 0.43 0.37 0.08 
Bmp8a 2.68 2.54 0.36 0.40 0.43 0.07 
Bmpr1b 2.67 2.60 0.12 0.35 0.34 0.04 
Egf 2.66 2.58 0.29 0.40 0.42 0.03 
Fgfr3 2.64 2.64 0.10 0.42 0.42 0.05 
Akp2 2.62 2.26 0.62 0.50 0.59 0.10 
Col1a1 2.61 2.63 0.27 0.43 0.44 0.03 
Col9a1 2.58 2.68 0.22 0.49 0.56 0.08 
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Col4a6 2.58 1.82 0.81 0.47 0.50 0.08 
Dspp 2.57 1.92 0.67 0.58 0.53 0.08 
Runx2 2.56 2.57 0.10 0.44 0.43 0.03 
Col10a1 2.54 2.11 0.66 0.51 0.51 0.07 
Enam 2.54 2.33 0.42 0.49 0.46 0.05 
Mmp2 2.50 3.04 0.58 0.71 0.80 0.19 
Smad7 2.49 2.53 0.06 0.40 0.40 0.02 
Bmp1 2.45 2.44 0.50 0.46 0.46 0.10 
ltga2 2.43 2.43 0.06 0.45 0.50 0.05 
Tgfbr3 2.42 1.87 0.76 0.54 0.64 0.14 
ltga2b 2.40 1.70 0.77 0.65 0.75 0.14 
Col15a1 2.36 2.34 0.65 0.54 0.45 0.15 
Smad9 2.35 2.26 0.10 0.43 0.39 0.04 
Mmp9 2.31 2.21 0.26 0.54 0.54 0.06 
Tnf 2.30 2.14 0.49 0.52 0.62 0.12 
Fgfr2 2.30 2.24 0.20 0.45 0.42 0.07 
Sost 2.29 2.30 0.10 0.44 0.45 0.01 
Ctsk 2.27 2.43 0.46 0.65 0.41 0.27 
Col6a2 2.26 2.19 0.33 0.61 0.45 0.16 
Smad5 2.26 2.21 0.07 0.44 0.42 0.02 
Smad6 2.26 2.25 0.06 0.43 0.45 0.03 
Anxa5 2.24 2.82 0.65 0.82 0.75 0.29 
Tgfb1 2.24 2.29 0.06 0.43 0.40 0.03 
Bmp3 2.23 2.16 0.14 0.45 0.53 0.08 
lcam1 2.22 2.15 0.12 0.44 0.45 0.06 
Col7a1 2.22 2.64 0.42 0.50 0.45 0.11 
Tgfbr1 2.21 2.16 0.05 0.42 0.42 0.00 
Flt1 2.20 1.84 0.79 0.68 0.53 0.16 
Col4a2 2.17 1.73 0.50 0.60 0.53 0.14 
Vegfa 2.14 1.93 0.21 0.48 0.47 0.02 
Bmp4 2.12 2.29 0.21 0.51 0.56 0.11 
Tuft1 2.12 2.14 0.06 0.51 0.41 0.12 
Col3a1 2.12 1.83 0.68 1.13 0.60 0.66 
Smad4 2.06 1.78 0.29 0.46 0.52 0.10 
Smad1 2.00 1.87 0.25 0.44 0.44 0.04 
Csf3 1.99 1.91 0.45 0.57 0.62 0.11 
Cdh11 1.92 1.74 0.57 0.70 0.63 0.10 
Smad3 1.91 1.71 0.21 0.54 0.55 0.11 
Tfip11 1.91 1.87 0.04 0.46 0.46 0.12 
Twist2 1.91 1.81 0.10 0.43 0.41 0.03 
Col4a1 1.90 1.53 0.58 0.73 0.70 0.14 
Col9a3 1.90 1.29 0.66 0.69 0.77 0.13 
Bmpr2 1.85 1.72 0.44 0.61 0.58 0.15 
Fn1 1.85 2.02 0.45 0.82 0.84 0.11 
Serpinh1 1.85 1.15 0.74 0.72 0.88 0.21 
lgf1 1.81 1.84 0.15 0.60 0.53 0.09 
Ahsg 1.74 1.57 0.20 0.51 0.62 0.15 
Mmp10 1.73 1.72 0.19 0.59 0.70 0.12 
Tgfb2 1.71 1.95 0.26 0.49 0.44 0.06 
lgf1r 1.69 1.77 0.13 0.54 0.51 0.08 
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Tgfb3 1.64 1.30 0.48 0.71 0.81 0.17 
Twist1 1.60 1.44 0.38 0.66 0.68 0.15 
Scarb1 1.55 1.06 0.55 0.69 0.84 0.18 
Sox9 1.53 1.23 0.37 0.77 0.89 0.16 
Vdr 1.53 1.36 0.23 0.55 0.59 0.08 
Smad2 1.52 1.32 0.28 0.57 0.68 0.12 
Vegfb 1.48 1.32 0.62 0.72 0.74 0.16 
Col6a1 1.47 0.69 0.79 1.01 0.84 0.30 
Col8a1 1.47 1.35 0.45 1.00 0.83 0.30 
ltgb1 1.46 1.35 0.29 0.67 0.69 0.13 
Vegfc 1.44 1.39 0.07 0.53 0.56 0.04 
Col4a5 1.40 1.24 0.33 0.66 0.55 0.14 
Pdgfa 1.38 1.55 0.29 0.93 0.72 0.32 
Nfkb1 1.37 1.30 0.19 0.67 0.61 0.13 
Col1a2 1.32 1.35 0.16 0.91 0.91 0.04 
Mgp 1.30 1.37 0.29 0.84 0.73 0.21 
Tgfbr2 1.29 1.18 0.16 0.67 0.74 0.12 
Vcam1 1.25 1.04 0.23 0.78 0.92 0.16 
Col5a1 1.09 1.11 0.25 0.91 0.85 0.33 
Spp1 1.02 0.87 0.26 0.95 0.85 0.23 
Bgn 0.90 0.95 0.33 1.70 1.07 0.68 
Spare 0.77 0.99 0.23 1.61 0.83 0.79 
63 
Table 1 - Focused osteogenic microarray. MC3T3-El cells were cultured under 
mineralizing conditions and transfected with either FOXO 1 specific or scrambled siRNA as 
described in Materials and Methods. After 14 days total RNA was extracted and an 
osteogenic focused microarray was carried out as described in Materials and Methods. The 
mean and median values of three microarrays per assay condition are demonstrated when 
compared to the matching control. Values shown in bold illustrate changes where mean and 
median values demonstrated a minimum of 1. 7 fold increase or 0.6 fold decrease 
( corresponding to 1. 7 fold decrease). Thus the mean fold change met a minimum threshold 
and the median values ensure that not less than two out of the three microarrays 
independently met this threshold. 
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Figure 4: Comparison of mRNA levels obtained by microarray and real time PCR. 
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Figure 4: Comparison of mRNA levels obtained by microarray and real time PCR. 
Selected genes from the microarray were confirmed by real time PCR. MMP13, SMAD5, 
RUNX2 and type I collagen were tested. The data are presented as fold change between each 
experimental group and its control. A solid line corresponds to 1. 7 and 0.6 fold, which was 
the threshold utilized. (a) Increased by mineralizing cultures. (b) Decreased by FOXOl 
siRNA. 
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5 - RUNX2 DNA binding is regulated by FOXOl during osteoblast differentiation at 
the nuclear protein level. 
Since RUNX2 has an important role in the control of osteoblast maturation (Komori, 
2002), this assay was carried out to observe the possible effects of FOXO 1 knock down in 
RUNX-2 at the nuclear protein level (Fig. 5). MC3T3-El cells were cultured in media 
containing 50 µg/ml of ascorbic acid and 10 mM of p-glycerophosphate (mineralizing 
media) for 14 days. Two days after this treatment was initiated, a transient transfection with 
FOXO 1 siRNA and scrambled siRNA was conducted. Nuclear protein was obtained after 7 
and 14 days of culture in mineralizing media. The results showed an increase of 
approximately 2 fold (P<0.05) by the mineralizing cultures in RUNX2 DNA binding 
compared to cells not maintained in mineralizing media harvested prior to transfection and a 
decrease of approximately 50% (P<0.05) in RUNX2 DNA binding with FOXOl knock down 
compared to scrambled siRNA on both time points. 
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Figure 5: FOXOl siRNA reduced RUNX2 DNA binding in mineralizing cultures. 
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Figure 5: FOXOl siRNA reduced RUNX2 DNA binding in mineralizing cultures. 
MC3T3-El cells were cultured under mineralizing conditions and transfected with either 
FOXOl specific or scrambled siRNA as described in Materials and Methods. After 7 and 14 
days nuclear proteins were extracted and assay was carried out as described in Materials and 
Methods. Specificity of the assay was confirmed by reduced detection of RUNX2 in the 
sample treated with competitive oligonucleotides (comp.) and absence of competition with 
non competitive oligonucleotides (non-comp.). The data presented are the mean of three 
independent experiments ± SEM and are shown as percent of maximum stimulation. 
Asterisks indicate significantly increased values compared to day zero and double asterisks 
indicate significant reduction compared to cells treated with scrambled siRNA (P < 0.05). 
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6 - FOXOl and RUNX2 bind in adjacent regions in the promoter sequence of selected 
target genes. 
Since FOXO 1 was shown to participate in the regulation of RUNX2 during osteoblast 
differentiation, we identified FOXO 1 and RUNX2 consensus cis-elements in the promoter 
region of all target genes present in the focused osteogenic microarray. In particular, four 
different patterns of promoter sequence binding were consistent in FOXO 1 and RUNX2. The 
first pattern found was FOXOl binding in approximately one hundred base pairs prior to 
RUNX2 promoter binding, which was consistent in 28% of genes present in the array (Table 
2, column A). The second pattern found was RUNX2 binding in approximately one hundred 
base pairs prior to FOXOl promoter binding, which was consistent in 17% of genes present 
in the array (Table 2, column B). The third pattern was FOXOl binding immediately before 
RUNX2 in the promoter sequence, which was consistent in 9% of genes present in the array 
(Table 2, column C). Finally the fourth pattern was RUNX2 binding immediately before 
FOXO 1 in the promoter sequence which was consistent in 5% of genes present in the array 
(Table 2, column D). 
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Table 2: Comparison of FOXOl and RUNX2 binding sites in the promoter region of 
selected genes. 
A 
AHSG 
BMP4 
BMP7 
BMPR1A 
COL15A1 
COL4A3 
COL4A6 
COL15A1 
COL4A3 
COL4A6 
COMP 
CSF3 
DCN 
EGF 
FGF2 
GDF10 
ITGAB 
ITGA3 
ITGAB1 
MMP10 
MMP13 
SMAD3 
SMAD9 
SOST 
TFIP11 
TUFT1 
VEGFC 
B 
AMBM 
BMP6 
COL15A1 
COL4A2 
COL15A1 
COL4A5 
COL9A1 
CSF2 
CTSK 
DSPP 
EGF 
ITGA2 
MMP13 
MMP9 
MSX1 
NO 
SMAD4 
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C 
BMP3 
BMPR1A 
COL7A1 
COL7A1 
DCN 
IGF1 
MMP10 
NFKBN 
TFIP11 
D 
BMP1 
BMPSA 
COL4A4 
MMPS 
SDMAD2 
Table 2: Comparison of FOXOl and RUNX2 binding sites in the promoter region of 
selected genes. FOXO 1 and RUNX2 consensus cis-elements were identified in the promoter 
region of genes present in the osteogenic focused microarray. (Column A) FOXOl binds in 
approximately one hundred base pairs prior to RUNX2 in the promoter region of target genes 
from the osteogenic focused microarray. (Column B) RUNX2 binds in approximately one 
hundred base pairs prior to FOXO 1 in the promoter region of target genes from the 
osteogenic focused microarray. (Column C) FOXOl binds immediately before RUNX2 in 
the promoter region of target genes from the osteogenic focused microarray. (Column D) 
RUNX2 binds immediately before FOXO 1 in the promoter region of target genes from the 
osteogenic focused microarray. 
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7 - Alkaline phosphatase activity is regulated by FOXOl during osteoblast 
differentiation. 
Because alkaline phosphatase is known to be an important indicator for bone 
mineralization (Kim et al., 2004), this assay was performed after 7 and 14 days in 
mineralizing media (Fig. 6). MC3T3-El cells were cultured in media containing 50 µg/ml of 
ascorbic acid and 10 mM of p-glycerophosphate (mineralizing media) for 14 days. Two days 
after this treatment was initiated, a transient transfection with FOXO 1 siRNA and scrambled 
siRNA was conducted. Cytoplasmic protein was obtained after 7 and 14 days of culture in 
mineralizing media. The results indicate an increase of 2 fold on day 7 (P<0.05) and 3.5 fold 
on day 14 (P<0.05) in alkaline phosphatase activity compared to cells not maintained in 
mineralizing media harvested prior to transfection and a reduction of 41 % on day 7 (P>0.05) 
and 53% on day (P<0.14) in alkaline phosphatase activity with FOXOl knock down 
compared to scrambled siRNA. 
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Figure 6: FOXOl siRNA reduced alkaline phosphatase activity in mineralizing 
cultures. 
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Figure 6: FOXOl siRNA reduced alkaline phosphatase activity in mineralizing 
cultures. MC3T3-El cells were cultured under mineralizing conditions and transfected with 
either FOXOl specific or scrambled siRNA as described in Materials and Methods. After 7 
and 14 days cytoplasmic proteins were extracted and assay was carried out as described in 
Materials and Methods. The data presented are the mean of three independent experiments ± 
SEM and are shown as percent of maximum stimulation. Asterisks indicate significantly 
increased values compared to day zero and double asterisks indicate significant reduction 
compared to cells treated with scrambled siRNA (P < 0.05). 
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8 - The formation of mineralized nodules by MC3T3-El cells cultured in mineralizing 
media is regulated by FOXOl. 
MC3T3-El cells have been shown to have the capacity to form mineralized nodules 
upon stimulation with ascorbic acid and p-glycerophosphate (Sudo et al., 1983; Barbara et 
al., 2004). With the intention of inhibiting the formation of mineralized nodules, MC3T3-El 
cells were transfected with FOXOl siRNA or scrambled siRNA and maintained in normal 
conditions for a week. Cells were then cultured in media containing 50 µg/ml of ascorbic 
acid and 10 mM of p-glycerophosphate (mineralizing media) for another two weeks. 
Mineralized nodules were formed and stained with alizarin red (Fig. 7a-b). The stain was 
eluted and the acid soluble calcium bound dye was quantified in a spectrophotometer (Fig. 
7c). An increase of 4 fold in acid soluble calcium bound dye was obtained by the 
mineralizing cultures compared to cells not maintained in mineralizing media harvested prior 
to transfection. (P<0.05) and a reduction of approximately 50% was obtained in acid soluble 
calcium bound dye with FOXO 1 knock down compared to scrambled siRNA (P<0.05). In 
parallel, the number of nodules was counted and the area size measured to observe the effects 
of FOXO 1 knock down in nodule formation and growth (Table 3). Results indicated an 
approximate 50% reduction in the number (P<0.05) and total area of the nodules (P<0.05) 
with FOXO 1 knock down. However, no difference in the average area per nodule was 
detected after FOXOl was knocked down (P>0.05). 
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Figure 7: FOXOl siRNA reduces the formation of mineralized nodules in mineralizing 
cultures. 
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Figure 7: FOXOl siRNA reduces the formation of mineralized nodules in mineralizing 
cultures. MC3T3-El cells were transfected with either FOXOl specific or scrambled siRNA 
and kept under normal conditions for a week. Cells were then cultured under mineralizing 
conditions for approximately 2 weeks until mineralized nodules were formed as described in 
Materials and Methods. (a) Mineralized nodule visualized at l00X magnification. (b) 
Alizarin red staining of the mineralized nodules. ( c) Acid soluble quantification of the 
mineralized nodules. The data presented are the mean of three independent experiments ± 
SEM and are shown as percent of maximum stimulation. Asterisks indicate significantly 
increased values compared to day zero and double asterisks indicate significant reduction 
compared to cells treated with scrambled siRNA (P < 0.05). 
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Table 3 - FOXOl siRNA reduces the average nodule number and the total nodules 
area, but not the average area per nodule. 
Group Name Average Nodule Total Nodule Average Area 
Number area (mm2) per Nodule 
(nodule/mm2) 
Mineralization 44 ± 2.1 0.002 ± 0.0003 21639.3 
Scrambled siRNA 
+ Mineralization 45 ± 3.8 0.002 ± 0.0005 22750.4 
FOXO1siRNA 24* ± 0.6 0.001* ± 0.0002 27799.2 
+ Mineralization 
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Table 3: FOXOl siRNA reduces the average nodule number and the total nodules area, 
but does not reduce the average area per nodule. MC3T3-El cells were transfected with 
either FOXOl specific or scrambled siRNA and kept under normal conditions for a week. 
Cells were then cultured under mineralizing conditions for approximately 2 weeks until 
mineralized nodules were formed as described in Materials and Methods. The number of 
nodules formed was counted, the total nodules area was measured and the average area per 
nodule was assed by dividing the number of nodules by the total nodule area. The data 
presented are the mean of three independent experiments ± SEM. Asterisks indicate a 
significant reduction by FOXO 1 siRNA compared to cells treated with scrambled siRNA (P 
< 0.05). 
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9 - Lentiviral transduction. 
In order to confirm the sustained knock down of FOXOl after 14 days of transfection 
with siRNA, a stable transduction was conducted using a lentivirus construct that expressed 
FOXOl shRNA or scrambled shRNA. MC3T3-El cells were cultured in media containing 
50 µg/ml of ascorbic acid and 10 mM of p-glycerophosphate (mineralizing media) for 14 
days. Two days after this treatment was initiated, a stable transduction with FOXO 1 shRNA 
and scrambled shRNA containing green fluorescence protein was conducted. Total RNA was 
extracted after 14 days of culture in mineralizing media. FOXOl, RUNX2 and osteocalcin 
mRNA levels were measured by real time PCR (Fig. 8b-d). Green fluorescence protein was 
detected only in transducted cells and showed a transduction efficiency close to 100% (Fig. 
8a). The results obtained by real time PCR showed an increase of 1. 7 fold (P<0.05) in 
FOXO 1 mRNA levels after 14 days of culture in mineralizing media compared to cells not 
maintained in mineralizing media harvested prior to transduction and a decrease of 52% 
(P<0.05) in FOXO 1 with FOXO 1 inhibition compared to scrambled shRNA. When RUNX2 
was tested a 3 fold increase was obtained after 14 days of culture in mineralizing media 
compared to cells not maintained in mineralizing media harvested prior to transfection 
(P<0.05) and FOXO 1 inhibition down-regulated RUNX2 by 51 % compared to scrambled 
shRNA (P<0.05) (Fig.7c). Osteocalcin showed an elevation of 100 fold after 14 days of 
culture in mineralizing media compared to cells not maintained in mineralizing media 
harvested prior to transfection (P<0.05) and a reduction of 69% with FOXO 1 inhibition 
compared to scrambled shRNA (P<0.05). Thus the lentivirus transduction confirmed the 
previous siRNA results. 
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Figure 8: FOXOl shRNA decreased RUNX2 and Osteocalcin mRNA levels after 14 
days of culture in mineralizing media. 
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Figure 8: FOXOl shRNA decreased RUNX2 and Osteocalcin mRNA levels after 14 
days of culture in mineralizing media. MC3T3-El cells were cultured under mineralizing 
conditions and transducted with either FOXOl specific or scrambled shRNA as described in 
Materials and Methods. After 14 days of culture in mineralizing media green fluorescence 
protein was detected and total RNA extracted. The mRNA levels of FOXO 1, RUNX2 and 
osteocalcin were measured by real time PCR and normalized to ribosomal protein L32 as 
described in Materials and Methods. (a) Green fluorescence protein detection in transducted 
cells. (b) FOXO 1 mRNA levels. ( c) RUNX2 mRNA levels. ( d) Osteocalcin mRNA levels. 
The data presented are the mean of three independent experiments ± SEM and are shown as 
percent of maximum stimulation. Asterisks indicate significantly increased values compared 
to day zero and double asterisks indicate significant reduction compared to cells treated with 
scrambled siRNA (P < 0.05). 
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10 - Cytokines induce FOXOl at nuclear protein and mRNA levels in MC3T3-El cells. 
To investigate the impact of FOXOl in osteoblastic cell apoptosis, in vitro assays 
were carried out with MC3T3-El cells. Cells were transfected with FOXOl siRNA or 
scrambled siRNA; 48 hours later, cells were stimulated with 5 ng/ml each of TNF-a, IL-lP 
and IFN-y alone or the three combined for 48 hours. FOXOl DNA binding assay and 
FOXOl mRNA levels (Fig. 9) were carried out. When tested alone, TNF-a did not induce 
increased FOXO 1 DNA binding at doses that did in fibroblastic cells (Alikhani et al., 2005a; 
Alikhani et al., 2005b). However, when TNF-a was combined with IL-lP and IFN-y there 
was increase of2 fold in FOXOl DNA binding (P<0.05) compared to unstimulated cells. IL-
IP and IFN-y together had no effect (P>0.05). The impact of FOXOl siRNA was also tested, 
and a reduction of 54% in FOXOl DNA binding was found in cytokine stimulated cells 
compared to scrambled siRNA (P<0.05) (Fig. 9a). The combination of TNF-a, IL-lP and 
IFN-y also increased FOXOl mRNA levels by 1.5 fold compared to unstimulated (P<0.05). 
Knockdown of FOXOl by siRNA reduced FOXOl mRNA levels also by 56% in cytokine 
stimulated MC3T3-El cells versus scrambled siRNA (P<0.05) (Fig. 9b). 
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Figure 9: FOXOl siRNA decreased cytokine stimulation at the nuclear protein level 
and at FOXOl mRNA levels in MC3T3-El cells. 
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Figure 9: FOXOl siRNA decreased cytokine stimulation at the nuclear protein level 
and at FOXOl mRNA levels in MC3T3-El cells. MC3T3-El cells were treated with or 
without IFN-y, IL-lP and TNF-a (individual or mixture as indicated in the figure). Cells 
treated with cytokine mixture were pre-transfected with either FOXOl specific or scrambled 
siRNA as described in Materials and Methods. Nuclear protein and total RNA were 
extracted. (a) FOXOl DNA binding assay was performed as described in Materials and 
Methods. Specificity of the assay was confirmed by reduced detection of FOXO 1 in the 
sample treated with competitive oligonucleotides (comp.) and absence of competition with 
non competitive oligonucleotides (non-comp.) (b) FOXOl mRNA levels were assayed by 
real time PCR and normalized to ribosomal protein L32 as described in Materials and 
Methods. The data presented are the mean of three independent experiments ± SEM and are 
shown as percent of maximum stimulation. Asterisks indicate significantly increased values 
compared to day zero and double asterisks indicate significant reduction compared to cells 
treated with scrambled siRNA (P < 0.05). Abbreviations: In, INF-y; IL, IL-Ip; T, TNF-a. 
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11 - Cytokine-induced apoptosis in MC3T3-El cells is regulated by FOXOl. 
The role of innate and adaptive immune cytokines in apoptosis of osteoblastic 
MC3T3-El cells was also investigated. MC3T3-El cells were transfected with FOXOl 
siRNA or scrambled siRNA. 48 hours later, cells were stimulated with 5 ng/ml each of TNF-
a, IL-1 J3 and IFN-y alone or combined for 48 hours. Apoptosis assay and caspase 3/7 
activity were performed (Fig. 10). TNF-a alone and IL-1J3 and IFN-y together had almost no 
effect on apoptosis. However, the stimulation with a combination ofIL-1(3, TNF-a and IFN-
y induced apoptosis by approximately 2.5 fold compared to compared to unstimulated cells 
(P<0.05). The role of FOXOl in apoptosis was assessed by knockdown with RNAi. FOXOl 
siRNA significantly reduced apoptosis of MC3T3-El cells by approximately 60% in cells 
stimulated with TNF-a, IL-1J3 and IFN-y compared to scrambled siRNA (P<0.05) (Fig. 
lOA). Similarly , the combination of cytokines stimulated caspase-3/7 activity by 2 fold 
compared to unstimulated. Knockdown of FOXO 1 also reduced caspase-3/7 activity in 
cytokine stimulated cells by approximately 60% compared to scrambled siRNA (P<0.05) 
(Fig. 10b). 
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Figure 10: FOXOl siRNA decreased cytokine-induced apoptosis in MC3T3-El cells. 
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Figure 10: FOXOl siRNA decreased cytokine-induced apoptosis in MC3T3-El cells. 
MC3T3-El cells were treated with or without IFN-y, IL-IP and TNF-a (individual or 
mixture as indicated in the figure). Cells treated with cytokine mixture were pre-transfected 
with either FOXOl specific or scrambled siRNA as described in Materials and Methods. (a) 
Apoptosis assay was performed by ELISA as described in Materials and Methods. (b) 
Caspase-3/7 activity was carried out with cytoplasmic protein as described in Materials and 
Methods. The data presented are the mean of three independent experiments ± SEM and are 
shown as percent of maximum stimulation. Asterisks indicate significantly increased values 
compared to day zero and double asterisks indicate significant reduction compared to cells 
treated with scrambled siRNA (P < 0.05). Abbreviations: In, INF-y; IL, IL-Ip; T, TNF-a. 
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12 - Cytokine-induced gene expression of pro-apoptotic genes in MC3T3-El cells is 
regulated by FOXOl. 
To further explore mechanisms by which FOXOl may contribute to osteoblast 
apoptosis, MC3T3-El cells were transfected with FOXOl siRNA or scrambled siRNA and 
stimulated with 5 ng/ml of TNF-a, IL-1~ and IFN-y alone or combined for 48 hours as 
described in Materials and Methods. Total RNA was extracted and pro-apoptotic genes such 
as caspase-3, caspase-8, caspase-9, TNF-a and FADD were examined at mRNA levels by 
real time PCR (Fig. 11 ). Caspase-3 was 2.2 fold increased by cytokines stimulation compared 
to unstimulated cells (P<0.05) and 64% decreased by FOXO 1 knock down compared to 
scramble siRNA (P<0.05) (Fig. lla). Caspase-8, was 1.7 fold increased by cytokines 
stimulation compared to unstimulated cells (P<0.05) and 53% decreased by FOXOl knock 
down compared to scramble siRNA (P<0.05) (Fig. 11 b ). Caspase-9 was 1.6 fold increased by 
cytokines stimulation compared unstimulated cells (P<0.05) and 42% decreased by FOXO 1 
knock down compared to scramble siRNA (P<0.05) (Fig. l lc). TNF-a was increased 17 fold 
by cytokines stimulation compared to unstimulated cells (P<0.05), and was reduced by 52% 
compared to scrambled siRNA (P<0.05) (Fig. 1 0d). F ADD was 17 fold increased by 
cytokines stimulation compared to unstimulated cells harvested (P<0.05) and 61 % decreased 
by FOXOl knock down compared to scramble siRNA (P<0.05) (Fig. 1 le). 
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Figure 11: FOXOl siRNA decreases cytokine-induced apoptosis at mRNA levels in 
MC3T3-El cells. 
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Figure 11: FOXOl siRNA decreases cytokine-induced apoptosis at mRNA levels in 
MC3T3-El cells. MC3T3-El cells were treated with or without IFN-y, IL-lp and TNF-a 
(individual or mixture as indicated in the figure). Cells treated with cytokine mixture were 
pre-transfected with either FOXOl specific or scrambled siRNA as described in Material and 
Methods. Total RNA was extracted and mRNA levels of selected pro-apoptotic genes were 
tested by real time PCR and normalized to ribosomal protein L32 as described in Materials 
and Methods. (a) Caspase-3 mRNA levels. (b) Caspase-8 mRNA levels. (c) Caspase-9 
mRNA levels. (d) TNF-a mRNA levels. (e) FADD mRNA levels. The data presented are the 
mean of three independent experiments ± SEM and are shown as percent of maximum 
stimulation. Asterisks indicate significantly increased values compared to day zero and 
double asterisks indicate significant reduction compared to cells treated with scrambled 
siRNA (P < 0.05). Abbreviations: In, INF-y; IL, IL-lp; T, TNF-a. 
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13 - C3H10Tl/2 cells BMP2 stimulated (hypertrophic chondrocytes) express type II and 
type X collagen at mRNA levels. 
C3H10Tl/2-stem mesenchymal cells were stimulated with 100 ng/ ml of BMP2 for 4 
days. mRNAs levels of type II collagen and type X collagen was assessed by real time PCR 
as described in Materials and Methods to ensure cell commitments into the chondrogenic 
phenotype. The results indicate an up-regulation of 5 fold and 16 fold respectively in type II 
and type X collagen by BMP2 compared to cells not stimulated with BMP2 (P<0.05) (Table 
4). 
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Table 4: mRNA levels of type II and type X collagen in C3H10Tl/2 cells stimulated with 
BMP2. 
Type II Collagen mRNA (percent maximum) Fold Change 
Negative Control 0.19 ± 0.02 
BMP2 1 5.2* 
Type X Collagen mRNA (percent maximum) Fold Change 
Negative Control 0.06 ± 0.03 
BMP2 1 16.6* 
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Table 4: mRNA levels of type II and type X collagen in C3Hl0Tl/2 cells stimulated with 
BMP2. 
C3H10Tl/2 cells were stimulated with BMP2 as described in Materials and Methods. Total 
RNA was extracted and type II and type X collagen mRNA levels were carried out by real 
time PCR and normalized to ribosomal protein L32 as described in Materials and Methods. 
The data presented are the mean of three independent experiments ± SEM and are shown as 
percent of maximum stimulation. Asterisks indicate significantly increased values compared 
to negative control. 
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14 - C3H10Tl/2 cells only respond to TNF-a stimulation after BMP2 stimulation. 
C3Hl 0Tl/2 mesenchymal stem cells were stimulated with 100 ng/ml of BMP2 for 4 
days or maintained in standard media. Cells were then submitted to different doses of TNF-a 
(5 ng/ml, 10 ng/ml or 20 ng/ml); FOXOl DNA binding assay, FOXOl, TNF-a, IL-6 and 
caspase-3 mRNA levels and apoptosis assay were carried out as described in Materials and 
Methods (Fig. 12a-f). Nuclear proteins were obtained and FOXOl DNA binding was 
performed. Results indicate that FOXOl did not respond to TNF-a stimulation while kept in 
standard media (Fig. 12a), but once this cells were stimulated with BMP2 (hypertrophic 
chondrocytes), FOXOl DNA binding was significantly increased by 10 ng/ml and 20 ng/ml 
of TNF-a, which resulted in an increase of 1.5 fold and 2 fold respectively in FOXOl DNA 
binding compared to cells without TNF-a. No significant change was found with 3 ng/ml of 
TNF-a (Fig. 12b). The same study was performed at mRNA levels by real time PCR, the 
results that confirmed that this cell type only gains the capacity to respond to TNF-a upon 
BMP2 stimulation (hypertrophic chondrocytes with BMP2). No changes at the mRNA levels 
of FOXOl (Fig. 12c), TNF-a (Fig. 12e), caspase-3 (Fig. 12g) and IL-6 (Fig. 12i) were 
obtained. After BMP2 stimulation (hypertrophic chondrocytes ), significant changes were 
obtained in the same genes tested with stimulation of either 10 ng/ml or 20 ng/ml of TNF-a, 
with a fold change of 1.9 and 2.2 in FOXOl (P<0.05) (Fig. 12d), 9 and 11 fold in TNF-a 
(P<0.05) (Fig. 12f), 2.6 and 4.1 fold in caspase-3 (P<0.05) (Fig. 12h) and 11 and 16 fold in 
IL-6 compared to cells without TNF-a (P<0.05) (Fig. 12j). There was no significant change 
after stimulation with 3 ng/ml of TNF-a in all the genes tested. Moreover, the same dose 
response study was performed to observe if C3H10Tl/2 cells could undergo apoptosis 
through TNF-a stimulation. Results showed that when cells were kept in standard media, 
100 
apoptosis did not occur independently of the TNF-a dose utilized (Fig. 12k). However, when 
the cells were stimulated with BMP2 (hypertrophic chondrocytes), an increase of 2.3 and 2.8 
fold (P<0.05) in apoptosis was obtained with TNF-a in both doses, 10 ng/ml and 20 ng/ml 
compared to cells without TNF-a. Stimulation with 3 ng/ml of TNF-a did not result in a 
significant fold change (Fig. 121). 
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Figure 12: TNF-a. only affects C3H10Tl/2 after BMP2 stimulation at the nuclear 
protein and mRNA levels and well as cell apoptosis. 
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Figure 12: TNF-a only affects C3H10Tl/2 after BMP2 stimulation at the nuclear 
protein and mRNA levels and well as cell apoptosis. C3Hl0Tl/2 cells were stimulated 
with BMP2 (hypertrophic chondrocytes) or maintained in standard media as described in 
Materials and Methods. Cells were then treated in a dose response mode with or without 
TNF-a. (a) FOXOl DNA binding assay in C3HlOTl/2 cells not stimulated with BMP2. (b) 
FOXOl DNA binding assay in BMP2 stimulated C3HlOTl/2 cells (hypertrophic 
chondrocytes). Specificity of the assay was confirmed by reduced detection of FOXOl in the 
sample treated with competitive oligonucleotides (comp.) and absence of competition with 
non competitive oligonucleotides (non-comp.). (c) FOXOl mRNA levels in C3HlOTl/2 
cells not stimulated with BMP2. (d) FOXOl mRNA levels in BMP2 stimulated C3HlOTl/2 
cells (hypertrophic chondrocytes). (e) TNF-a mRNA levels in C3HlOTl/2 not stimulated 
with BMP2. (f) TNF-a mRNA levels in BMP2 stimulated C3HlOTl/2 cells (hypertrophic 
chondrocytes). (g) Caspase-3 mRNA levels in C3HlOTl/2 not stimulated with BMP2. (h) 
Caspase-3 mRNA levels in BMP2 stimulated C3HlOTl/2 cells (hypertrophic chondrocytes). 
(i) IL-6 mRNA levels in C3Hl OTl/2 cells not stimulated with BMP2. G) IL-6 mRNA levels 
in BMP2 stimulated C3Hl OTl/2 cells (hypertrophic chondrocytes). (k) Apoptosis assay in 
C3Hl OTl/2 cells not stimulated with BMP2. (1) Apoptosis assay in BMP2 stimulated 
C3Hl OTl/2 cells (hypertrophic chondrocytes). The data presented are the mean of three 
independent experiments + SEM and are shown as percent of maximum stimulation. 
Asterisks indicate significantly increased values compared to cells without TNF-a 
stimulation (P < 0.05). 
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15 - ATDCS cells BMP2 stimulated (hypertrophic chondrocytes) express type II and 
type X collagen at mRNA levels. 
A TDC5 chondrogenic cells were stimulated with 200 ng/ml of BMP2 for 6 days. 
mRNAs levels of type II collagen and type X collagen was assessed by real time PCR. The 
results indicate an up-regulation 3.2 fold and 33.3 fold respectively in type II and type X 
collagen by BMP2 compared to cells not stimulated with BMP2 (P<0.05) (Table 5). 
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Table 5: mRNA levels of type II and type X collagen in ATDCS cells stimulated with 
BMP2. 
Type II Collagen mRNA (percent maximum) Fold Change 
Negative Control 0.31 ± 0.04 
BMP2 1 3.2* 
Type X Collagen mRNA (percent maximum) Fold Change 
Negative Control 0.03 ± 0.01 
BMP2 1 33.3* 
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Table 5: mRNA levels of type II and type X collagen in ATDC5 cells stimulated with 
BMP2. A TDC5 cells were stimulated with BMP2 as described in Materials and Methods. 
Total RNA was extracted and type II and type X collagen mRNA levels were carried out by 
real time PCR and normalized to ribosomal protein L32 as described in Materials and 
Methods. The data presented are the mean of three independent experiments ± SEM and are 
shown as percent of maximum stimulation. Asterisks indicate significantly increased values 
compared to negative control. 
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16 - TNF-a.-induced FOXOl at the nuclear protein level in chondrocytes. 
To examine the effects of TNF-a at FOXOl nuclear protein level in chondrocytes, 
A TDC5 cells were stimulated with BMP2 or maintained in standard media. Cells were then 
transfected with FOXO siRNA or scrambled siRNA and stimulated with 20 ng/ml of TNF-a 
as described in the Materials and Methods. Nuclear protein was isolated and FOXOl DNA 
binding assay was carried out (Fig.13). Results showed that in cells not stimulated with 
BMP2, FOXO 1 DNA binding was increased by approximately 2 fold when stimulated with 
TNF-a compared to cells without TNF-a (P<0.05), and 60% decreased with FOXOl knock 
down compared to scrambled siRNA (Fig.13a). In BMP2 stimulated cells (hypertrophic 
chondrocytes) an increase of 1.9 fold on FOXOl DNA binding was obtained by TNF-a 
stimulation compared to cells without TNF-a (P<0.05), and a reduction of approximately 
67% was obtained by FOXOl knock down compared to scramble siRNA (P<0.05) (Fig 13b). 
Results showed that TNF-a-induced FOXO 1 at the nuclear protein level in A TDC5 cells 
stimulated or nor with BMP2. 
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Figure 13: FOXOl siRNA reduces TNF-a. stimulation in ATDC5 cells at the nuclear 
protein level. 
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Figure 13: FOXOl siRNA reduces TNF-a. stimulation in ATDCS cells at the nuclear 
protein level. A TDC5 cells were stimulated with BMP2 or maintained in standard media as 
described in Materials and Methods. Cells were then treated with or without TNF-a. Cells 
treated with TNF-a were pre-transfected with either FOXOl specific or scrambled siRNA. 
Nuclear proteins were extracted and FOXO 1 DNA binding activity was carried out as 
described in Materials and Methods. (a) FOXOl DNA binding assay in ATDC5 cells not 
stimulated with BMP2. (b) FOXO 1 DNA binding assay in ATDC5 cells BMP2 stimulated 
(hypertrophic chondrocytes ). Specificity of the assay was confirmed by reduced detection of 
FOXO 1 in the sample treated with competitive oligonucleotides (comp.) and absence of 
competition with non competitive oligonucleotides (non-comp). The data presented are the 
mean of three independent experiments ± SEM and are shown as percent of maximum 
stimulation . Asterisks indicate significantly increased values compared to negative control or 
to BMP2 stimulated cells not treated with TNF-a. Double asterisks indicate significant 
reduction compared to cells treated with scrambled siRNA (P < 0.05). 
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17 -TNF-a.-induced FOXOl mRNA levels are increased in BMP2 stimulated cells 
(hypertrophic chondrocytes ). 
To investigate the impact of TNF-a and FOXOl in chondrocytes, ATDC5 and 
C3H10Tl/2 cells were stimulated with BMP2 or maintained in standard media; cells were 
then transfected with FOXO siRNA or scrambled siRNA and stimulated TNF-a as described 
in Materials and Methods. Total RNA was extracted and FOXO 1 mRNA levels were 
assessed by real time PCR (Fig.14). TNF-a stimulation increased FOXOl mRNA levels by 
approximately 2.4 fold in ATDC5 cells not stimulated with BMP2 compared to cells without 
TNF-a (P<0.05). When FOXOl was knocked down a reduction of 59% in FOXOl mRNA 
levels was obtained, compared to scrambled siRNA (P<0.05) (Fig. 14a). ATDC5 cells BMP2 
stimulated (hypertrophic chondrocytes) achieved a 3.8 fold increase in FOXOl mRNA with 
TNF-a stimulation compared to cells without TNF-a (P<0.05). FOXOl knock down down-
regulated this effect by decreasing FOXOl mRNA levels in 71 % compared to scrambled 
siRNA (P<0.05) (Fig. 14b). C3H10Tl/2 BMP2 stimulated (hypertrophic chondrocytes) 
increased FOXOl mRNA levels in 3 fold with TNF-a stimulation compared to cells without 
TNF-a (P<0.05). FOXOl knock down down-regulated this effect by reducing FOXOl 
mRNA level in 82% compared to scrambled siRNA (P<0.05) (Fig. 14c ). 
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Figure 14: FOXOl mRNA is elevated in BMP2 stimulated cells (hypertrophic 
chondrocytes ). 
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Figure 14: FOXOl mRNA is elevated in BMP2 stimulated cells (hypertrophic 
chondrocytes). ATDC5 and C3H10Tl/2 cells were stimulated with BMP2 or maintained in 
standard media. Cells were treated with or without TNF-a. Cells treated with TNF-a were 
pre-transfected with either FOXOl specific or scrambled siRNA as described in Materials 
and Methods. Total RNA was extracted; FOXOl mRNA levels were measured by real time 
PCR and normalized to ribosomal protein L32 as described in Materials and Methods. (a) 
FOXO 1 mRNA levels A TDC5 not stimulated with BMP2. (b) FOXO 1 mRNA levels in 
A TDC5 cells BMP2 stimulated (hypertrophic chondrocytes ). ( c) FOXO 1 mRNA levels in 
C3H10Tl/2 cells BMP2 stimulated (hypertrophic chondrocytes). The data presented are the 
mean of three independent experiments ± SEM and are shown as percent of maximum 
stimulation. Asterisks indicate significantly increased values compared to negative control or 
to BMP2 stimulated cells not treated with TNF-a. Double asterisks indicate significant 
reduction compared to cells treated with scrambled siRNA (P < 0.05). 
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18 - TNF-a.-induced mRNA levels of TNF-a. is increased in BMP2 stimulated cells 
(hypertrophic chondrocytes) and is regulated by FOXOl. 
To examme the effects of TNF-a on TNF-a gene expression in chondrocytes, 
ATDC5 and C3H10Tl/2 cells were stimulated BMP2 or maintained in standard media. Cells 
were then transfected with FOXO siRNA or scrambled siRNA and stimulated of TNF-a as 
described on Materials and Methods. Total RNA was extracted and TNF-a mRNA levels 
were tested by real time PCR (Fig.15). TNF-a stimulation increased TNF-a gene expression 
by approximately 2.4 fold in ATDC5 cells not stimulated with BMP2 compared to cells 
without TNF-a (P<0.05). When FOXOl was knocked down a reduction of 58% in TNF-a 
mRNA levels was obtained compared to scrambled siRNA (P<0.05) (Fig. 15a). ATDC5 cells 
BMP2 stimulated (hypertrophic chondrocytes) achieved a 49 fold increase in TNF-a mRNA 
levels with TNF-a stimulation compared to cells without TNF-a (P<0.05). FOXO 1 knock 
down down-regulated this effect by decreasing TNF-a mRNA levels in 58% compared to 
scrambled siRNA (P<0.05) (Fig. 15b). C3H10Tl/2 cells BMP2 stimulated (hypertrophic 
chondrocytes) were 5 fold increased TNF-a mRNA levels with TNF-a stimulation compared 
to cells without TNF-a (P<0.05). FOXOl knock down down-regulated this effect by 
decreasing TNF-a mRNA levels in 85% when compared to scrambled siRNA (P<0.05) (Fig. 
15c). 
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Figure 15: TNF-a. mRNA levels are elevated in BMP2 stimulated cells (hypertrophic 
chondrocytes) and are reduced by FOXOl siRNA. 
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Figure 15: TNF-a. mRNA levels are elevated in BMP2 stimulated cells (hypertrophic 
chondrocytes) and are reduced by FOXOl siRNA. ATDC5 and C3Hl 0Tl/2 cells were 
stimulated with BMP2 or maintained in standard media as described in Materials and 
Methods. Cells were treated with or without TNF-a. Cells treated with TNF-a were pre-
transfected with either FOXOl specific or scrambled siRNA as described in Materials and 
Methods. Total RNA was extracted; TNF-a mRNA levels was assessed by real time PCR 
and normalized to ribosomal protein L32 as described in Materials and Methods. (a) TNF-a 
mRNA levels in ATDC5 cells not stimulated with BMP2. (b) TNF-a mRNA levels in 
ATDC5 cells BMP2 stimulated (hypertrophic chondrocytes). (c) TNF-a mRNA levels in 
C3H10Tl/2 cells BMP2 stimulated (hypertrophic chondrocytes). The data presented are the 
mean of three independent experiments + SEM and are shown as percent of maximum 
stimulation. Asterisks indicate significantly increased values compared to negative control or 
to BMP2 stimulated cells not treated with TNF-a. Double asterisks indicate significant 
reduction compared to cells treated with scrambled siRNA (P < 0.05). 
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19- TNF-a-induced mRNA levels of pro-inflammatory cytokines and chemokines in 
BMP2 stimulated cells (hypertrophic chondrocytes) is regulated by FOXOl. 
To discover if the mechanism by which TNF-a-induced inflammation was regulated 
by FOXOl in BMP2 stimulated cells (hypertrophic chondrocytes); ATDC5 and C3H10Tl/2 
cells were stimulated with BMP2, transfected with FOXO siRNA or scrambled siRNA and 
stimulated with TNF-a as described in Materials and Methods. Total RNA was extracted and 
the mRNA levels of IL-1 a, IL-6, CCL3 and CCL4 were tested by real time PCR (Fig. 16). 
The mRNA levels of IL-la were 23 fold increased by TNF-a in ATDC5 cells BMP2 
stimulated (hypertrophic chondrocytes) compared to cells without TNF-a (P<0.05). A 
reduction of 58% in IL-la was found when FOXOl was knocked down by siRNA compared 
to scrambled siRNA (P<0.05) (Fig.16a). When the mRNA levels of IL-la were tested in 
C3H10Tl/2 cells BMP2 stimulated (hypertrophic chondrocytes) an increase of 12 fold in IL-
la was obtained with TNF-a stimulation compared to cells without TNF-a (P<0.05) and a 
decrease of 93% in IL-la was obtained by FOXOl knock down compared to scrambled 
siRNA (P<0.05) (Fig. 16b ). IL-6 mRNA was 84 fold up-regulated with TNF-a stimulation 
A TDC5 cells BMP2 stimulated (hypertrophic chondrocytes) compared to cells without TNF-
a (P<0.05) and 84% down-regulated in IL-6 was obtained when FOXOl was knocked down 
compared to scrambled siRNA (P<0.05) (Fig. 16c). In C3H10Tl/2 cells BMP2 stimulated 
(hypertrophic chondrocytes ), IL-6 mRNA levels increased 49 fold with TNF-a stimulation 
compared to cells without TNF-a (P<0.05) and a decreased 93% with FOXOl knock down 
compared to scrambled siRNA (P<0.05) (Fig. 16d). When the mRNA levels of CCL-3 were 
assessed in A TDC5 cells BMP2 stimulated (hypertrophic chondrocytes ), an increase of 4 7 
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fold in CCL3 was obtained with TNF-a stimulation compared to cells without TNF-a 
(P<0.05) and a decrease of 70% in CCL3 was obtained by FOXOI knock down compared to 
scrambled siRNA (P<0.05) (Fig. 16e ). CCL3 mRNA levels were 92 fold increased in 
C3H10Tl/2 cells BMP2 stimulated (hypertrophic chondrocytes) with TNF-a treatment 
compared to cells without TNF-a (P<0.05) and 96% decreased with FOXO 1 knock down 
compared to scrambled siRNA (P<0.05) (Fig. l 6f). CCL4 mRNA levels were up-regulated 
by 24 fold with TNF-a stimulation in ATDC5 cells BMP2 stimulated (hypertrophic 
chondrocytes) compared to cells without TNF-a and 70% down-regulated by FOXOI knock 
down compared to scrambled siRNA (P<0.05) (Fig. 16g). CCL4 mRNA levels were 90 fold 
increased in C3H10Tl/2 cells BMP2 stimulated (hypertrophic chondrocytes) with TNF-a 
treatment compared to cells without TNF-a (P<0.05) and 88% decreased with FOXOI knock 
down compared to scrambled siRNA (P<0.05) (Fig. 16i). These results suggest that FOXO 1 
plays an important role in the regulation of TNF-a-induced inflammation in BMP2 
stimulated cells (hypertrophic chondrocytes ). 
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Figure 16: FOXOl siRNA reduces TNF-a.-induced inflammation at the mRNA levels of 
cytokines and chemokines in BMP2 stimulated cells (hypertrophic chondrocytes). 
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Figure 16: FOXOl siRNA reduces TNF-a.-induced inflammation in cytokines and 
chemokines in BMP2 stimulated cells (hypertrophic chondrocytes). ATDC5 and 
C3H10Tl/2 cells were stimulated with BMP2, transfected with FOXOl specific or 
scrambled siRNA and stimulated with TNF-a as described in Materials and Methods. Total 
RNA was extracted; IL-1 a, IL-6, CCL3 and CCL4 mRNA levels were measured by real time 
PCR and normalized to ribosomal protein L32 as described in Materials and Methods. 
(a) IL-la mRNA levels in ATDC5 cells BMP2 stimulated (hypertrophic chondrocytes). 
(b) IL-la mRNA levels in C3H10Tl/2 cells BMP2 stimulated (hypertrophic chondrocytes). 
( c) IL-6 mRNA levels in A TDC5 cells BMP2 stimulated (hypertrophic chondrocytes ). 
(d) IL-6 mRNA levels in C3H10Tl/2 cells BMP2 stimulated (hypertrophic chondrocytes). 
(e) CCL3 mRNA levels in ATDC5 cells BMP2 stimulated (hypertrophic chondrocytes). 
(f) CCL3 mRNA levels in C3H10Tl/2 cells BMP2 stimulated (hypertrophic chondrocytes). 
(g) CCL4 mRNA levels in A TDC5 cells BMP2 stimulated (hypertrophic chondrocytes ). 
(h) CCL-4 mRNA levels in C3H10Tl/2 cells BMP2 stimulated (hypertrophic chondrocytes). 
The data presented are the mean of three independent experiments ± SEM and are shown as 
percent of maximum stimulation. Asterisks indicate significantly increased values compared 
to BMP2 stimulated cells not treated with TNF-a and double asterisks indicate significant 
reduction compared to cells treated with scrambled siRNA (P < 0.05). 
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20 - TNF-a-induced pro-osteoclastogenic factors in BMP2 stimulated cells 
(hypertrophic chondrocytes) is regulated by FOXOl. 
To determine if TNF-a-induced inflammation would lead to the induction of the pro-
osteoclastogenic genes RANKL and CSF-1; and also to observe if this possible induction 
would be regulated by FOXO 1 in BMP2 stimulated cells (hypertrophic chondrocytes ), 
ATDC5 and C3H10Tl/2 cells were stimulated with BMP2, transfected with FOXO siRNA 
or scrambled siRNA and stimulated with TNF-a as described in Materials and Methods. 
Total RNA was extracted and the mRNA levels of RANKL and CSF-1 were tested by real 
time PCR. (Fig.17). The mRNA levels of RANKL were 8 fold increased with TNF-
a stimulation in A TDC5 cells BMP2 stimulated (hypertrophic chondrocytes) compared to 
cells without TNF-a (P<0.05). A reduction of 66% in RANKL was found when FOXOl was 
knocked down by FOXO 1 siRNA compared to scrambled siRNA (P<0.05) (Fig.17a). When 
RANKL was tested in C3 H 1 OT 1/2 cells BMP2 stimulated (hypertrophic chondrocytes) an 
up-regulation of 6 fold with TNF-a stimulation was obtained compared to cells without 
TNF-a (P<0.05) and a down-regulation in RANKL of78% was obtained with FOXOl knock 
down compared to scrambled siRNA (P<0.05) (Fig. 17b). CSF-1 was 9 fold increased with 
TNF-a stimulation in A TDC5 cells BMP2 stimulated (hypertrophic chondrocytes) compared 
to cells without TNF-a (P<0.05). A 66% decrease in CSF-1 was obtained with FOXOl 
knock down compared to scrambled siRNA (P<0.05) (Fig. 17c). In C3H10Tl/2 cells BMP2 
stimulated (hypertrophic chondrocytes), CSF-1 was 4.5 fold enhanced with TNF-a 
stimulation compared to cells without TNF-a (P<0.05) and a 76% decreased in CSF-1 was 
achieved with FOXOl knock down compared to scrambled siRNA (P<0.05) (Fig. 17d). 
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These results suggest that FOXOl might be involved in the regulation of TNF-a-induced 
osteoclastogenesis in BMP2 treated cells (hypertrophic chondrocytes ). 
130 
Figure 17: FOXOl siRNA reduces TNF-a-induced osteoclastogenesis in BMP2 
stimulated cells (hypertrophic chondrocytes ). 
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Figure 17: FOXOl siRNA reduces TNF-a.-induced osteoclastogenesis in BMP2 
stimulated cells (hypertrophic chondrocytes). ATDC5 and C3H10Tl/2 cells were 
stimulated with BMP2, transfected with FOXO 1 specific or scrambled siRNA and stimulated 
with TNF-a as described in Materials and Methods. Total RNA was extracted; RANKL and 
CSF-1 mRNA levels were measured by real time PCR and normalized to ribosomal protein 
L32 as described in Materials and Methods. 
(a) RANKL mRNA levels in ATDC5 cells BMP2 stimulated (hypertrophic chondrocytes). 
(b) RANKL mRNA levels in C3H10Tl/2 cells BMP2 stimulated (hypertrophic 
chondrocytes ). ( c) CSF-1 mRNA levels in A TDC5 cells BMP2 stimulated (hypertrophic 
chondrocytes ). 
(d) CSF-1 mRNA levels in C3H10Tl/2 cells BMP2 stimulated (hypertrophic chondrocytes). 
The data presented are the mean of three independent experiments ± SEM and are shown as 
percent of maximum stimulation. Asterisks indicate significantly increased values compared 
to BMP2 stimulated cells not treated with TNF-a and double asterisks indicate significant 
reduction compared to cells treated with scrambled siRNA (P < 0.05). 
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21 - FOXOl regulates TNF-a.-induced chemokines at the mRNA levels of ATDCS cells 
BMP2 stimulated (hypertrophic chondrocytes ). 
To explore in more detail the role of FOXOl in BMP2 stimulated chondrocytes 
during the inflammatory process, a chemokines and receptors focused microarray was carried 
out. A TDC5 cells were stimulated with BMP2 as described in Materials and Methods. Cells 
were then transfected with FOXO siRNA or scrambled siRNA and stimulated with TNF-a. as 
described in Materials and Methods. Total RNA was extracted and a focused microarray was 
performed as described in Materials and Methods (Table 6). The results indicate 55% of the 
genes present in the microarray were up-regulated by TNF-a. stimulation compared to cells 
without TNF-a., and 45% of the genes present were down-regulated by FOXO 1 knock down 
compared to scrambled siRNA. Important inflammatory mediators such as TNF-a., IL-
1 a., CCL4 and Cxcl 10 were 1000 fold, 23 fold, 29 fold and > 1000 fold respectively increased 
with TNF-a. stimulation compared to cells not treated with TNF-a. (P<0.05), and 0.001 fold, 
0.18 fold, 0.03 fold and <0,001 fold respectively decreased by FOXOl knock down 
compared to scrambled siRNA (P<0.05). Overall, these results confirmed the importance of 
FOXO 1 in the regulation of pro-inflammatory genes at the mRNA level. 
Selected genes from the microarray were confirmed by Real Time PCR. TNF-a., 
CCL-4 and CSF-1 were tested (Fig.18). The data is presented as logl0 fold change between 
each experimental group and its control. 
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Table 6: Chemokines and receptors focused microarray. 
Increased by TNF-a. Decreased by FOX01 knock down 
Fold Change P-Value Fold Change P-Value 
Tnf >1000 0.00 <0.001 0.00 
Cxcl10 >1000 0.00 <0.001 0.00 
Ccl2 >1000 0.02 0.05 0.00 
Ccl20 >1000 0.00 0.03 0.00 
Ccl5 >1000 0.04 0.02 0.00 
lnhbb >1000 0.25 <0.001 0.32 
Cxcl9 >1000 0.00 0.00 0.00 
Cx3cl1 724.28 0.08 0.07 0.00 
Ccrl2 653.19 0.00 0.01 0.00 
Ccl9 212.20 0.00 0.04 0.00 
Xcl1 124.30 0.58 0.02 0.61 
Csf1 102.28 0.15 0.16 0.00 
Ccl7 95.40 0.00 0.04 0.00 
Cxcl13 88.10 0.10 1.14 0.86 
Actb 82.83 0.32 0.68 0.04 
Cxcl11 82.10 0.32 <0.001 0.00 
Ccl17 59.28 0.00 0.07 0.00 
Nfkb1 49.74 0.19 0.31 0.00 
Cxcl2 48.74 0.00 0.11 0.00 
Cmtm4 45.88 0.24 0.78 0.03 
Ccr6 40.15 0.09 1.06 0.89 
Bmp10 37.51 0.02 0.03 0.01 
Ccl4 29.60 0.05 0.03 0.00 
Hif1a 24.80 0.35 0.95 0.70 
111a 23.53 0.00 0.18 0.00 
Lif 17.85 0.42 0.67 0.89 
Tnfrsf1a 14.70 0.31 0.98 0.79 
Tlr4 14.10 0.26 1.07 0.82 
Ppbp 13.78 0.30 0.70 0.00 
Cxcl1 12.55 0.02 0.30 0.00 
Ccl8 12.44 0.00 0.29 0.00 
1118 11.77 0.13 0.77 0.00 
Cxcl5 11.34 0.00 0.17 0.00 
Tnfsf14 7.88 0.18 0.16 0.23 
Ccr4 7.43 0.07 0.74 0.04 
Ccl1 6.13 0.04 0.19 0.05 
Cmtm6 6.02 0.03 0.59 0.00 
Ccl11 5.86 0.30 0.24 0.20 
Bdnf 5.66 0.18 0.64 0.04 
Csf2 5.09 0.62 0.29 0.00 
Ccr1 4.46 0.05 0.23 0.05 
Cxcr5 4.28 0.06 0.81 0.73 
Ccr10 3.86 0.56 11.14 0.19 
Mmp2 3.46 0.12 1.10 0.47 
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1113 3.39 0.37 1.49 0.62 
Cxcl15 3.31 0.56 0.13 0.06 
Rgs3 2.81 0.10 0.56 0.46 
Cxcl12 2.78 0.57 2.36 0.00 
114 2.77 0.32 1.46 0.44 
Ccr3 2.31 0.54 0.20 0.03 
Bmp6 1.83 0.36 0.75 0.12 
Ccr9 1.81 0.43 1.20 0.61 
Ccr7 1.69 0.44 0.75 0.39 
Myd88 1.51 0.78 0.32 0.00 
II8ra 1.47 0.29 2.09 0.19 
Ccr1I1 1.35 0.80 0.85 0.89 
Cxcr6 1.35 0.28 1.22 0.07 
lnha 1.27 0.77 3.36 0.00 
RTC 1.25 0.74 0.65 0.07 
RTC 1.21 0.77 0.68 0.13 
Tymp 1.21 0.16 1.94 0.01 
PPC 1.11 0.87 0.99 0.94 
Cmtm3 1.09 0.90 0.96 0.66 
Cxcr3 0.95 0.99 0.70 0.61 
Ccl6 0.94 0.99 0.06 0.02 
Cmklr1 0.88 0.91 1.59 0.04 
Ccr2 0.83 0.90 0.99 0.99 
RTC 0.73 0.80 0.86 0.45 
Cxcr7 0.67 0.87 0.50 0.00 
Cxcr4 0.52 0.00 3.33 0.00 
118rb 0.50 0.83 0.15 0.09 
Cera 0.44 0.71 0.47 0.23 
Gusb 0.40 0.32 1.41 0.00 
Hsp90ab1 0.40 0.29 1.05 0.41 
Trem1 0.39 0.41 1.48 0.63 
Ccl19 0.37 0.78 0.25 0.43 
Ccrl1 0.32 0.40 2.28 0.14 
Ccr5 0.30 0.68 0.40 0.28 
Hprt1 0.23 0.38 1.00 0.98 
Agtrl1 0.22 0.68 0.35 0.43 
Cx3cr1 0.20 0.71 0.93 0.96 
Bmp15 0.18 0.31 4.48 0.08 
Ccbp2 0.18 0.09 3.74 0.17 
Pf4 0.16 0.63 0.52 0.13 
Ccl12 0.15 0.49 2.50 0.40 
Gdf5 0.11 0.23 8.19 0.08 
MGDC 0.07 0.57 0.37 0.35 
PPC 0.07 0.65 55.44 0.40 
Cmtm5 0.05 0.45 1.48 0.63 
Gpr81 0.05 0.53 0.54 0.47 
1116 0.05 0.41 0.56 0.64 
Slit2 0.05 0.41 0.82 0.47 
Ltb4r2 0.03 0.32 2.38 0.03 
Cmtm2a 0.02 0.24 0.64 0.64 
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PPC 0.02 0.41 1437.01 0.14 
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Table 6: Chemokines and receptors focused microarray. ATDC5 cells were stimulated 
with BMP2, transfected with FOXOl specific or scrambled siRNA and stimulated with TNF-
a as described in Materials and Methods. Total RNA was extracted and a chemokines and 
receptors microarray was carried out as described in Materials and Methods. Balded values 
represent changes where at least 1. 7 fold increase or 0.6 fold decrease was obtained, as well 
as P < 0.05. 
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Figure 18: Microarray validation by real time PCR. 
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Figure 18: Microarray validation by real time PCR. ATDC5 cells were stimulated BMP2. 
Cells were then transfected with FOXO 1 specific or scrambled siRNA and stimulated with 
TNF-a as described in Materials and Methods. Total RNA was extracted and selected genes 
from the microarray were confirmed by real time PCR. TNF-a, CCL4 and CSF-1 were tested 
and normalized to ribosomal protein L32. The graph is presented as logl0 fold change scale 
to assist in the analysis. Solid lines corresponds to 0.23 (loglO equivalent of 1.7 fold) and 
dashed lines corresponds to -0.23 (logl0 equivalent of 0.6 fold), which were the threshold 
utilized. The data presented are the mean of three independent experiments ± SEM and are 
shown as percent of maximum stimulation 
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22 - FOXOl regulates TNF-a. at the cytoplasmic protein level in cells stimulated with 
BMP2 (hypertrophic chondrocytes ). 
To further examine the correlation between FOXOl and TNF-a, TNF-a levels were 
measured by ELISA in cytoplasmic protein. A TDC5 cells were stimulated with BMP2, 
transfected with FOXO siRNA or scrambled siRNA and stimulated with TNF-a as described 
in Materials and Methods. The cytoplasmic proteins were extracted and TNF-a levels were 
measured by ELISA (Fig. 19). Results indicated an increase of approximately 2 fold in TNF-
a with TNF-a stimulation compared cells without TNF-a (P<0.05) and a reduction of 42% 
in TNF-a with FOXOl knock down compared to scrambled siRNA (P>0.05). 
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Figure 19: FOXOl siRNA reduces TNF-a at the protein level in BMP2 stimulated cells 
(hypertrophic chondrocytes ). 
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Figure 19: FOXOl siRNA reduces TNF-a. at the protein level in BMP2 stimulated cells 
(hypertrophic chondrocytes ). A TDC5 cells were stimulated with BMP2, transfected with 
either FOXOl specific or scrambled siRNA and stimulated with TNF-a as described in 
Materials and Methods. Cytoplasmic proteins were extracted and TNF-a ELISA was carried 
out as described in Materials and Methods. The data presented are the mean of three 
independent experiments ± SEM and are shown as percent of maximum stimulation. 
Asterisks indicate significantly increased values compared to BMP2 stimulated cells not 
treated with TNF-a and double asterisks indicate significant reduction compared to cells 
treated with scrambled siRNA (P < 0.05). 
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23 - TNF-a-induced apoptosis is regulated by FOXOl in BMP2 stimulated cells 
(hypertrophic chondrocytes ). 
Apoptosis is a fundamental process for endochondral bone formation (Gibson, 1998). 
Apoptosis assays were carried out in ATDC5 and C3H10Tl/2 cells maintained in standard 
media or BMP2 stimulated (hypertrophic chondrocytes) as described in Materials and 
Methods. Cells were transfected with FOXO siRNA or scrambled siRNA and stimulated 
with 20 ng/ml of TNF-a as described in Materials and Methods. The results indicate that 
TNF-a stimulation caused an up-regulation of 7 fold in apoptosis in A TDC5 cells not 
stimulated with BMP2 compared to cells without TNF-a (P<0.05). A reduction of 59% in 
apoptosis was obtained after FOXOl was knocked down in compare to scrambled siRNA 
(P<0.05) (Fig. 20a), while an increase of 5 fold and a decrease of 58% in apoptosis was 
achieved with TNF-a stimulation and FOXO 1 knock down in BMP2 stimulated cells 
(hypertrophic chondrocytes) compared to cells not treated with TNF-a or to scrambled 
siRNA (P<0.05) (Fig. 20b). When caspase 3/7 activity was performed TNF-a stimulation 
increased caspase 3/7 activity by 5 fold compared to cells without TNF-a and FOXOl knock 
down reduced it by 75%, when compared to scramble (P<0.05) (Fig. 20c). 
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Figure 20: FOXOl siRNA decreased TNF-a-induced apoptosis in BMP2 stimulated 
cells (hypertrophic chondrocytes ). 
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Figure 20: FOXOl siRNA decreased TNF-induced apoptosis in BMP2 stimulated cells 
(hypertrophic chondrocytes ). ATDC5 cells were differentiated stimulated with BMP2 or 
maintained in standard media. Cells were then treated with or without TNF-a. Cells treated 
with TNF-a were pre-transfected with either FOXO 1 specific or scrambled siRNA as 
described in Materials and Methods. Apoptosis assay and caspase 3/7 activity were 
performed as described in Materials and Methods. (a) Apoptosis assay in ATDC5 cells not 
stimulated with BMP2. (b) Apoptosis assay in A TDC5 cells BMP2 stimulated (hypertrophic 
chondrocytes) . (c) Caspase-3/7 activity in ATDC5 cells BMP2 stimulated (hypertrophic 
chondrocytes) . The data presented are the mean of three independent experiments± SEM and 
are shown as percent of maximum stimulation. Asterisks indicate significantly increased 
values compared to BMP2 stimulated cells not treated with TNF-a and double asterisks 
indicate significant reduction compared to cells treated with scrambled siRNA (P < 0.05). 
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24 - TNF-a-induced pro-apoptotic factors in BMP2 stimulated cells (hypertrophic 
chondrocytes) is regulated by FOXOl. 
The mRNA levels of pro-apoptotic genes were tested to observe if FOXO 1 was 
involved in the regulation of TNF-induced apoptosis in BMP2 stimulated cells (hypertrophic 
chondrocytes). ATDC5 and C3H10Tl/2 cells were stimulated with BMP2, transfected with 
FOXO siRNA or scrambled siRNA and stimulated with TNF-a as described in Materials and 
Methods. Total RNA was extracted and the mRNA levels of caspase-3, caspase-8, caspase-9 
and TRAIL were tested by real time PCR (Fig.21 ). Caspase-3 mRNA levels were 1.9 fold 
increase with TNF-a stimulation in A TDC5 cells BMP2 stimulated (hypertrophic 
chondrocytes) compared to cells without TNF-a stimulation (P<0.05). A reduction of 63% 
was found caspase-3 mRNA levels when FOXOl was knocked down by FOXOl siRNA 
compared to scrambled siRNA (P<0.05) (Fig.2la). When caspase-3 was tested in 
C3H10Tl/2 cells BMP2 stimulated (hypertrophic chondrocytes) an up-regulation of 4 fold 
was obtained with TNF-a stimulation compared to cells without TNF-a stimulation (P<0.05) 
and a down-regulation of 61 % in caspase-3 was found when FOXOl was knocked down by 
FOXO 1 siRNA compared to scrambled siRNA (P<0.05) (Fig. 21 b ). Caspase-8 was 1.9 fold 
increased with TNF-a stimulation in A TDC5 cells BMP2 stimulated (hypertrophic 
chondrocytes) compared to cells without TNF-a (P<0.05) and a 49% decrease in caspase-8 
was obtained when FOXOl was knocked down by FOXOl siRNA compared to scrambled 
siRNA (P<0.05) (Fig. 21c). In C3H10Tl/2 cells BMP2 stimulated (hypertrophic 
chondrocytes ), caspase-8 was 3 fold enhanced with TNF-a stimulation compared to cells 
without TNF-a (P<0.05) and a reduction of 52% was achieved when FOXO 1 was knocked 
down compared to scrambled siRNA (P<0.05) (Fig. 21d). Caspase-9 was 2.3 fold increased 
148 
in A TDC5 cells BMP2 stimulated (hypertrophic chondrocytes) with TNF-a stimulation 
compared to cells without TNF-a (P<0.05) and a reduction of 62% in caspase-9 was found 
when FOXOl was knocked down by FOXOl siRNA compared to scrambled siRNA 
(P<0.05) (Fig. 21e). Caspase-9 was 3 fold increased in C3H10Tl/2 cells BMP2 stimulated 
(hypertrophic chondrocytes) with TNF-a stimulation compared to cells without TNF-a 
(P<0.05) and a decrease of 60% in caspase-9 with FOXO 1 knock down was obtained 
compared to scrambled siRNA (P<0.05) (Fig. 2lf). TRAIL was 5.1 fold up-regulated by 
TNF-a stimulation in A TDC5 cells BMP2 stimulated (hypertrophic chondrocytes) with 
TNF-a stimulation compared to cells without TNF-a (P<0.05) and 59% down-regulated with 
FOXOl knock down compared to scrambled siRNA (P<0.05) (Fig. 21g). In C3H10Tl/2 cells 
BMP2 stimulated (hypertrophic chondrocytes), TRAIL was 48 fold enhanced by TNF-a 
stimulation compared to cells without TNF-a stimulation (P<0.05) and a reduction of 98% in 
TRAIL was achieved when FOXOl was knocked down compared to scrambled siRNA 
(P<0.05) (Fig. 21h). These results suggest that FOXOl mediates TNF-a-induced apoptosis in 
BMP2 stimulated cells (hypertrophic chondrocytes ). 
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Figure 21: FOXOl siRNA decreases TNF-a-induced apoptosis in BMP2 stimulated 
cells (hypertrophic chondrocytes) at mRNA levels. 
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Figure 21: FOXOl siRNA decreases TNF-a-induced apoptosis in BMP2 stimulated 
cells (hypertrophic chondrocytes) at mRNA levels. ATDC5 and C3H10Tl/2 cells were 
stimulated with BMP2 or maintained in standard media. Cells were then treated with or 
without TNF-a. Cells treated with TNF-a were pre-transfected with either FOXOl specific 
or scrambled siRNA as described in Materials and Methods. Total RNA was extracted; the 
mRNA levels of selected pro-apoptotic genes were tested by real time PCR and normalized 
to ribosomal protein L32 as described in Materials and Methods. 
(a) Caspase-3 mRNA levels in ATDC5 cells BMP2 stimulated (hypertrophic chondrocytes). 
(b) Caspase-3 mRNA levels in C3Hl 0Tl/2 cells BMP2 stimulated (hypertrophic 
chondrocytes ). 
(c) Caspase-8 mRNA levels in ATDC5 cells BMP2 stimulated (hypertrophic chondrocytes). 
(d) Caspase-8 mRNA levels in C3H10Tl/2 cells BMP2 stimulated (hypertrophic 
chondrocytes ). 
(e) Caspase-8 mRNA levels in ATDC5 cells BMP2 stimulated (hypertrophic chondrocytes). 
(f) Caspase-8 mRNA levels in C3Hl 0Tl/2 cells BMP2 stimulated (hypertrophic 
chondrocytes ). 
(g) Caspase-9 mRNA levels in ATDC5 cells BMP2 stimulated (hypertrophic chondrocytes). 
(h) Caspase-9 mRNA levels in C3H10Tl/2 cells BMP2 stimulated (hypertrophic 
chondrocytes). (i) TRAIL mRNA levels in ATDC5 cells BMP2 stimulated (hypertrophic 
chondrocytes ). 
G) TRAIL mRNA levels in C3H10Tl/2 cells BMP2 stimulated (hypertrophic chondrocytes). 
The data presented are the mean of three independent experiments + SEM and are shown as 
percent of maximum stimulation. Asterisks indicate significantly increased values compared 
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to cells without TNF-a stimulation and double asterisks indicate significant reduction 
compared to cells treated with scrambled siRNA (P < 0.05). 
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25 - Intrinsic and extrinsic apoptotic pathways are activated during TNF-a-induced 
apoptosis in BMP2 stimulated cells (hypertrophic chondrocytes). 
To determine whether TNF-induced apoptosis lead to the activation of both intrinsic 
and extrinsic apoptotic pathways, initial studies were carried out utilizing the caspase-8 and 
caspase-9 inhibitors IETD-FMK and LEHD-FMK in BMP2 stimulated cells (hypertrophic 
chondrocytes ). A TDC5 cells were stimulated with BMP2 as described in Materials and 
Methods. Cells were then incubated with caspase-8 and 9 inhibitors combined or not and 
stimulated with TNF-a. Apoptosis assay was performed as described in Materials and 
Methods. Results indicate that both intrinsic and extrinsic apoptotic pathways work together, 
inhibiting TNF-a-induced apoptosis when combined by 84% (P<0.05). Interestingly, when 
caspase-8 or caspase-9 inhibitors were tested separately, only a partial inhibition of TNF-a 
stimulation was observed in the apoptosis assay (P>0.05). TNF-a stimulation increased 
apoptosis by 6 fold (P<0.05) (Fig. 22). 
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Figure 22: The combination of caspase-8 and 9 inhibitors block TNF-a.-induced 
apoptosis in BMP2 stimulated cells (hypertrophic chondrocytes). 
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Figure 22: The combination of caspase-8 and 9 inhibitors block TNF-a-induced 
apoptosis in BMP2 stimulated cells (hypertrophic chondrocytes). ATDC5 cells were 
stimulated with BMP2. Cells were then treated with or without TNF-a. Cells treated with 
TNF-a were incubated with of caspase-8 and 9 inhibitors alone or combined, simultaneously 
with TNF-a stimulation as described in Materials and Methods. Apoptosis assay was carried. 
The data presented are the mean of three independent experiments + SEM and are shown as 
percent of maximum stimulation. Asterisks indicate significantly increased values compared 
to cells without TNF-a stimulation and double asterisks indicate significant reduction 
compared to cells treated caspase-8 and 9 inhibitors (P < 0.05). 
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26 - ROS are involved in the activation of FOXOl by TNF-a. 
Reactive oxygen species (ROS) inhibitors NAC and trolox were tested in BMP2 
stimulated cells (hypertrophic chondrocytes) to observe if ROS were involved in the 
activation of FOXOl at the nuclear protein and mRNA levels during TNF-a stimulation 
(Fig. 23). ATDC5 cells were stimulated with BMP2; cells were then pre-incubated with 5 
mM or 10 mM of ROS inhibitors followed TNF-a stimulation as described in Materials and 
Methods. FOXO 1 DNA binding assay and FOXO 1 mRNA levels were assessed. The results 
demonstrated that at the nuclear protein level, FOXOl DNA binding was approximately 50% 
decreased by both inhibitors compared to TNF-a (P<0.05) and TNF-a was approximately 
2.5 fold increased compared to cells without TNF-a (P<0.05) (Fig. 23a). At FOXOl mRNA 
levels, both ROS inhibitors were approximately 45% decreased compared to TNF-a 
(P<0.05), and TNF-a was 2 fold increased compared to cells without TNF-a (P<0.05) (Fig. 
23b). 
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Figure 23: ROS inhibitors reduced TNF-a.-induced FOXOl at the nuclear protein and 
mRNA levels in BMP2 stimulated cells (hypertrophic chondrocytes). 
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Figure 23: ROS inhibitors reduced TNF-a-induced FOXOl at the nuclear protein and 
mRNA levels in BMP2 stimulated cells (hypertrophic chondrocytes ). A TDC5 cells were 
stimulated with BMP2. Cells were then treated with or without TNF-a. Cells treated with 
TNF-a were pre-treated with ROS inhibitors NAC or trolox as described in Materials and 
Methods. Nuclear proteins and total RNA was extracted (a) FOXOl DNA binding assay was 
performed as described in Materials and Methods. Specificity of the assay was confirmed by 
reduced detection of FOXOl in the sample treated with competitive oligonucleotides (comp.) 
and absence of competition with non competitive oligonucleotides (non-comp.) (b) FOXO 1 
mRNA levels were tested by real time PCR and normalized to ribosomal protein L32 as 
described in Materials and Methods. The data presented are the mean of three independent 
experiments ± SEM and are shown as percent of maximum stimulation. Asterisks indicate 
significantly increased values compared to cells without TNF-a stimulation and double 
asterisks indicate significant reduction compared to cells treated ROS inhibitors (P < 0.05). 
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27 - ATDC5 cells DNA Isolation 
DNA was isolated from A TDC5 cells not stimulated with BMP2 as a learning process 
for the next step of this project, a CHIP assay. DNA was submitted or not to 15 minutes of 
enzymatic digestion, and later was either purified or kept unpurified as extracted. Only DNA 
submitted to the enzymatic digestion was visualized through an agarose gel (Fig. 24). Results 
showed that both purified and unpurified DNA can be observed however, the band of the 
purified DNA was much clearer. 
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Figure 24: DNA isolation from ATCDS cells submitted to enzymatic digestion. 
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Figure 24: DNA isolation from ATCD5 cells submitted to enzymatic digestion. A TDC5 
cells were cultured in standard media and DNA was isolated as a learning process for a future 
CHIP assay. 
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DISCUSSION 
Transcription factors are proteins that have the capacity of binding specific DNA sequences 
through DNA binding domains in the target genes, stimulating or repressing transcription 
initiation (Latchman, 1997). The pathophysiology of many disease processes can be 
understood in terms of changes in gene expression. Transcription factors that control 
inflammation and apoptosis are particularly important in this regard. Inappropriate activity of 
transcription factors has been shown to promote a number of pathologies including 
atherosclerosis, cancer, arthritis, diabetes and other disorders (Eferl and Wagner, 2003; Liu 
and Pope, 2003; Monks et al., 2004; de Winther et al., 2005). 
TNF-a overproduction is thought to play a role in a number of disease processes 
associated with persistent inflammation and tissue destruction (Klimiuk et al., 2004; 
Ardizzone and Bianchi Porro, 2005; Graves et al., 2006). Increased levels of TNF-a are 
associated with innumerable complications of diabetes such as impaired wound and 
fracturure healing (Goova et al., 2001; Kayal et al., 2007) periodontal disease (Engebretson 
et al., 2007) and retinopathy (Ferris et al., 1999). TNF-a overexpression is actively involved 
in several diseases; any molecule that has the ability to block TNF-a may significantly 
improve health conditions of a considerable part of the population. Inhibition of TNF-a in 
diabetic animal models by subcutaneous injections of pegsunercept, which is a recombinant 
p55 monomeric, soluble TNF receptor type I linked to polyethylene glycol (PEG) (Furst et 
al., 2005), demonstrated improved wound healing (Siqueira, et al., unpublished data) and 
protection of the retinal microvasculature against apoptosis (Behl et al., 2008). However, the 
use of TNF inhibitors in clinical studies is controversial. Studies have suggested that a 
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significant proportion of patients with rheumatoid arthritis who are submitted to anti-TNF 
treatments have a latent increase in the susceptibility to infections like tuberculosis or 
pneumonia due to the fundamental role of TNF-a in inflammation (Kroesen et al., 2003 
Ellerin et al., 2003; Ranta et al., 2008). Another mechanism that could indirectly lead to 
TNF-a repression in vivo is the utilization of transcription factors that regulate TNF-a. Since 
FOXOl was demonstrated in this dissertation to be an important regulator of TNF-a-induced 
apoptosis and inflammation, a possible mechanism to reduce TNF-a overexpression in vivo 
would be the use of FOXO 1 inhibitors. An in vivo study by Altomonte et al showed a 
decrease in FOXOl expression though the use of a FOXOl inhibitor. This study utilized an 
adenovirus-mediated gene delivery system that transferred Foxol- , ... Q56 (amino domain of 
Foxol) to the livers of normal and diabetic db/db mice. Foxol-.U56 acted as a dominant 
negative mutant and proved to be a therapeutic approaching in diabetic animals by reducing 
PEPCK and G6Pase mRNA and diminishing blood glucose concentration (Altomonte et al., 
2003). Another in vivo study demonstrated that FOXOl knock down by siRNA in the retina 
of diabetic rats significantly decreased diabetes-enhanced retinal cell apoptosis (Behl, et al., 
unpublished data). In vitro RNAi experiments demonstrated that the ability of TNF-a to 
induce apoptosis was decreased by FOXO 1 knock down, and this decrease was accompanied 
by a reduction in caspase activity, revealing that FOXO 1 knock down was able to disrupt the 
post-translational pathways that arouse apoptosis through TNF-a (Alikhani et al., 2005a). 
Apoptosis has a critical function in the maintenance of bone, given that it controls the 
lifespan of osteoblasts (Manolagas, 2000). Osteoblasts apoptosis is considered an important 
mechanism to attract osteoclasts to particular bone areas during bone remodeling (Noble et 
al., 1997). Apoptosis also plays an important role in endochondral bone formation by 
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controlling the transition from chondrogenesis to osteogenesis, through the removal of 
hypertrophic chondrocytes to give place to ossification (Shapiro et al., 2005). To date, 
limited information is available about the role of FOXO 1 during bone formation. 
To understand the role of FOXOl in osteoblast differentiation, in vitro studies were 
carried out with the osteoblastic cell line MC3T3-El, which is a clonal murine calvarial-
derived cell line, originated from primary bone cell cultures that provide a model for the 
study of osteoblast differentiation. This cell line can undergo a developmental sequence 
similar to the osteoblast in bone tissue, exhibiting early proliferation of pre-osteoblasts 
followed by final osteoblast differentiation , characterized by the expression of alkaline 
phosphatase, formation of extra cellular matrix , and production of osteocalcin (Sudo et al., 
1983). It was previously reported that ascorbic acid and p-glycerophosphate are necessary for 
the expression of the mature osteoblast phenotype, which induces alkaline phosphatase and a 
mineralized extracellular matrix. Ascorbic acid is essential for the deposition of collagen in 
the extracellular matrix through the induction of osteoblast differentiation. P-
glycerophosphate has an important role in stimulating the mineralization of extracellular 
matrix in mature osteoblasts in synergy with ascorbic acid (Quarles et al., 1992). Our results 
demonstrates that MC3T3-El cells significantly increases the expression of alkaline 
phosphatase at the cytoplasmic protein level after two weeks of culture in mineralizing media 
and were able to mineralize the extracellular matrix formed within approximately three 
weeks. We also demonstrated that FOXO 1 was involved in the regulation of osteoblast 
differentiation by affecting the number of pre-osteoblasts that could differentiate into mature 
osteoblasts, through a reduction in nodule formation and total nodule area in cells transfected 
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with FOXOI siRNA. However, FOXOI did not reduce the average size per nodule in these 
cultures. Thus, FOXO I affects differentiation but not mineralization of osteoblasts. 
The effects of FOXOI during osteoblast differentiation were also observed in this 
study through FOXO I DNA binding and FOXO I mRNA levels, where FOXO I was elevated 
particularly after two weeks of culture in mineralizing media. Interestingly this up-regulation 
of FOXO I was synchronized with the results obtained by the alkaline phosphatase activity 
and by the focused osteogenic microarray, indicating a potential connection between FOXOI 
and osteoblast differentiation. To further investigate a possible connection FOXOI RNAi 
was carried out in all the mentioned assays and the results revealed that FOXO I was in fact 
affecting osteoblast differentiation. 
FOXO was recently demonstrated to regulate transcription responses independently 
of direct DNA binding through an association with numerous transcription factors, regulating 
sinergicaly the activation or repression of diverse target genes (van der Vos and Coffer, 
2008). An example of this synergic interaction can be observed with FOXO functional 
interaction with SMAD3 and 4 forming a complex that is critical to the control of cell growth 
and proliferation in response to TGFP (Seone et al., 2004). FOXO can also synergicly 
interact with P-catenin through increased levels of reactive oxygen species, suppressing 
osteoblast differentiation by limiting the interactions of P-catenin and TCF, which are 
required for osteoblast differentiation (Almeida et al., 2007). 
RUNX2 was shown by numerous studies to be crucial for osteoblast differentiation 
by regulating the expression of various osteoblastic genes such as type I collagen, 
osteopontin, and osteocalcin (Duey et al., 1997; Duey et al., 1999; Komori, 2003). 
Genetically modified mice with a deletion of both alleles of RUNX2 were shown to be born 
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with a cartilaginous skeleton (Komori et al., 1997). Since it is postulated that RUNX2 
actively participates in the regulation of osteoblast differentiation (Duey et al., 1997; Duey et 
al., 1999; Komori, 2003) we identified FOXO 1 and RUNX2 consensus cis-elements in the 
promoter region of all target genes present in the focused osteogenic microarray. In 
particular, we demonstrated four different patterns of promoter sequence binding consistently 
in FOXO 1 and RUNX2. Overall; we could observe a close proximity in the promoter binding 
sites on FOXOl and RUNX2 target genes, showing a synergic relation between these two 
transcription factors during the bone formation process, which was also confirmed by 
RUNX2 DNA binding assay as well as RUNX2 mRNA levels, where FOXOl knock down 
decreased RUNX2 at the nuclear protein and mRNA levels in mineralizing cultures. A 
logistic regression model, which is used to predict the probability of occurrence of an event 
by fitting data into a logistic curve, could be utilized in the future to discover how groups of 
genes are coordinately regulated during osteogenesis. 
Because siRNA is not commonly shown to work for long periods of time, a time 
course study with FOXO 1 siRNA and a lentivirus transduction expressing FOXO 1 shRNA 
were conducted in MC3T3-El cells cultured in mineralizing media. The results showed that 
the effects of both, siRNA and shRNA lasted for 14 days, confirming the results obtained in 
this study. Since FOXOl silencing sequence was different in FOXOl siRNA and FOXOl 
shRNA, the shRNA validation is considered stronger. 
The effect of acquired immune response or innate response in bone coupling has not 
been directly studied however, indirect evidence of T-lymphocytes supporting in vitro 
osteoclastogenesis (Colucci et al., 2007) and cytokines such as IL-1~, TNF-a and IFN-y 
regulating in osteoblast differentiation (Takayanagi, 2005) suggests that both innate immune 
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response and acquired immune response may be responsible synergistically responsible for 
reduced coupling. Since an increased expression of TNF-a, IL-1 p and IFN-y was previously 
determined by the immunization of mice against P. gingivalis , through a P. gingivalis 
injection adjacent to calvarial bone leading to a significantly enhanced FOXOl nuclear 
translocation in periosteal cells (Bell, et al., unpublished data), these cytokines were 
combined and tested in MC3T3-El cells to gain insight into mechanisms by which the 
acquired immune response could enhance osteoblastic cell apoptosis. This combination 
resulted in a significant increase in apoptosis consistent with results previously reported 
(Kuzushima et al., 2006), which demonstrated that the combination of TNF-a, IL-IP and 
IFN-y caused apoptosis, but not necrosis, through a double-staining method with annexin-V-
FITC and propidium iodine followed by an evaluation with a fluorescence-activated cell 
sorter Calibur (CellQuest). The cytokine combination also resulted in an increased caspase 
3/7 activity that confirmed the apoptosis result. When FOXOI was knocked down there was 
an equivalent reduction in the capacity of the cytokines to stimulate apoptosis and caspase-
3/7 activity. The knockdown of FOXOl also resulted in significant inhibition of the pro-
apoptotic genes TNF-a, FADD caspase-3, caspase-8 and caspase-9. 
Immune mediated inflammatory bone disease involves bone destruction and the 
formation of lytic lesions and to date the mechanism of their pathogenesis has not been 
clearly identified (Lorenzo, 2000). Results presented here indicate that a significant 
contribution of the acquired immune response to the formation of lytic lesions is the 
inhibition of coupling through diminished bone formation. The observation that cytokines of 
both innate and acquired immune system are required to induce osteoblast apoptosis can be 
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explained by the fact that osteoblasts are more resistant to apoptotic stimuli compared to 
many other cell types (Aizawa et al., 2001). 
FOXO 1 has been recently shown to play an important role in oxidative stress by 
inducing the expression of genes such as superoxide dismutase that reduce oxidative damage 
(Almeida et al., 2007). Thus the role of FOXOl as a pro-apoptotic factor appears paradoxical 
at first glance. However, it has been proposed that under conditions where activation is high 
or is prolonged, FOXO 1 functions as a pro-apoptotic factor (Sedding, 2008). This may be the 
case when the adaptive immune response is activated by bacterial infection. Thus, under 
conditions of a prolonged and strong host response, such as in periodontal disease where 
infection leads to both adaptive and innate immune mediated bone loss, both arms of the 
immune response may cause high and prolonged levels of FOXO 1 activation, apoptosis of 
bone cells and reduced coupling. 
Clinical studies have demonstrated the presence of a delayed fracture healing in 
diabetic patients (Cozen, 1972; Loder, 1988). Numerous studies suggested that diabetes 
impairs cartilage formation during fracture healing via a diminished differentiation and 
proliferation of chondrocytes (Topping et al., 1994; Gooch et al., 2000; Gandhi et al., 2005). 
Endochondral bone formation during fracture healing encompasses a multifaceted course of 
events. The development of the supporting callus is linked to cartilage formation, which is a 
vital requirement for the typical repair of long bones. Thus, it is believed that diabetes 
harmfully influences fracture healing by affecting cartilage formation or resorption (Kayal et 
al., 2007). TNF-a signaling coordinates the expression of factors that are critical for cartilage 
removal during fracture healing. The exact mechanism by which TNF-a affects 
osteoclastogenesis is controversial. TNF-a has been reported to have an indirect effect on 
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osteoclasts through RANKL stimulation (Hofbauer et al., 1999) and TNF-a has also shown 
to stimulate osteoclast differentiation in the presence of CSF-1 (Kobayashi et al., 2000). A 
study currently being carried out by Albolwi, et al proposes that diabetes increases TNF-a 
production and that this enhanced TNF-a plays a significant role in the fracture healing 
process by increasing osteoclastogenesis, since the inhibition of this enhanced TNF-a 
resulted in a 70 percent reduction in osteoclasts suggesting that diabetes enhanced 
osteoclastogenesis is mediated by TNF-a. 
Mesenchymal stem cells have the capacity of differentiating into osteoblasts, 
chondrocytes, adipocytes or miocytes depending on the signals to which they are exposed. 
Thus, mesenchymal stem cells are being used in cell-based therapies with the intention of 
repairing different kinds of tissues (Bruder et al., 1998; Caplan, 2005a). The pluripotent 
embryonic cell line C3H10Tl/2 has been shown to undergo chondrogenic differentiation in 
the presence of BMP2 (Reddi, 1998; Ju et al., 2000). Since it is known that mesenchymal 
C3H10Tl/2 cells are resistant to TNF-a stimulation (Fernandez, et al., 1994), we thought to 
investigate if this cell line would lose this TNF-a resistance once committed to the 
chondrocytic phenotype through BMP2 stimulation. Our results first confirmed that 
C3H10Tl/2 cells do not express any changes upon TNF-a stimulation while kept in the 
mesenchymal stage at FOXOI, TNF-a, IL-6 and caspase-3 mRNA levels, as well as on 
FOXOl DNA binding and apoptosis assay. However, once stimulated with BMP2 
(hypertrophic condrocytes ), this cell line started to be responsive to TNF-a stimulation in the 
same assays. 
In vitro studies were also performed with A TDC5 cells, a murine chondrocytic cell 
line used to study the multistep chondrogenic differentiation observed during endochondral 
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bone formation, including differentiation into type II collagen expressing chondrocytes, in 
the early phase differentiation, followed by type X collagen, expressed in terminal 
hypertrophic chondrocytes in the late phase of differentiation, which play a pivotal role in 
coordinating endochondral ossification; and finally apoptosis, induced by TNF-a (Atsumi et 
al., 1990.; Shukunami et al., 1998). Since C3Hl 0Tl/2 cells share similarities with ATDC5 
cells through the chondrogenic differentiation pathway after treatment with BMP2 (Hirao et 
al., 2006), we utilized A TDC5 cells in most assays due to its chondrocytic origin, which 
makes it more appropriated to the study of chondrocytes. Our results confirmed previous 
findings by showing that when ATDC5 and C3H10Tl/2 cells are stimulated with BMP2 
(hypertrophic chondrocytes) and later submitted to TNF-a stimulation, there was an increase 
in the expression of the pro-inflammatory and pro-oeteoclastogenic genes ILl-a, IL-6, TNF-
a, CSF-1, RANKL, CCL3 and CCL4. When FOXOl was knocked down there was an 
important diminution in the ability of TNF-a to stimulate the same pro-inflammatory and 
pro-oseoclastogenic genes, showing in this way the significance of this transcription factor in 
the regulation of all these processes. Another interesting finding was a more increased 
expression of FOXO 1 at mRNA as well as at the nuclear protein levels in cells stimulated 
with BMP2 (hypertrophic chondrocytes) other than in cells not stimulated with BMP2, and 
the results were later confirmed by in vivo studies through confocal laser scanning 
microscopy, where FOXO 1 nuclear translocation was demonstrated to be more elevated in 
hypertrophic chondrocytes other than in proliferative chondrocytes in diabetic mice 16 days 
after femur fracture (Albolwi, et al., unpublished data). Our findings suggest that FOXO 1 
might play a role in inflammatory bone disease by actively participating in the regulation of 
osteoclastogenesis and inflammation. 
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During endochondral bone formation, chondrocytes proliferate and later become 
hypertrophied. Chondocytes secrete a matrix that is mineralized and later removed by 
osteoclasts to be replaced by bone. Hypertrophic chondrocytes are then erased from the new 
bone by apoptosis. If apoptosis does not take place, there will be an equivalent rate of 
chondrocytes proliferation and maturation, which would lead to the formation of a chondroid 
bone with reduced mechanical, physical, and structural characteristics. Several studies 
confirmed this mechanism of removal of terminal hypertrophic chondrocytes by apoptosis 
(Gibson, 1998; Adams and Shapiro, 2002) however, a number of publications suggested that 
in vitro hypertrophic chondrocytes stay alive and differentiate into osteoblasts (Gentili et al., 
1993Galotto et al., 1994; Bianco et al., 1998). Our results showed that BMP2 stimulated 
chondrocytes (hypertrophic chondrocytes) death occurs via apoptosis when induced by TNF-
a. We demonstrated a significant increase in apoptosis after TNF-a stimulation in 
condrocytes treated with or without BMP2 and this results were further confirmed by 
caspase3/7 activity in BMP2 stimulated chondrocytes (hypertrophic chondrocytes ). FOXO 1 
knock down reduced TNF-a-induced apoptosis, confirming again the importance of this 
transcription factor in the regulation of TNF-a-induced apoptosis, as previously shown by 
Alikhani et al. (Alikhani et al., 2005a). mRNA levels of the pro-apoptotic genes caspase-3, 
caspase-8, caspase-9 and TRAIL also demonstrated a significant increase in apoptosis 
subsequent to TNF-a stimulation, and FOXO 1 knock down was able to diminish gene 
expression of these pro-apoptotic genes, demonstrating once again the ability of FOXO 1 in 
modulating TNF-a. 
Apoptosis occurs through two major pathways, mitochondrial and death receptor 
pathways (Alikhani et al., 2005b; Li et al., 1998). A study by Do et all demonstrated that 
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apoptosis takes place through the activation of only the death receptor pathway in T cells 
induced by beta-estradiol-17-valerate (Do et al., 2002). In contrast, a study by Werdehausen 
et all showed that in apoptosis occurs through the activation of the mitochondrial pathway in 
lymphoma cells induced by lidocaine (Werdehausen et al., 2007). Since apoptosis is involved 
in a large fraction of our studies we thought to investigate if both pathways were necessary 
for the occurrence of TNF-a-induced apoptosis in ATDC5 cells BMP2 stimulated 
(hypertrophic chondrocytes) through the use of caspase-8 and caspase-9 inhibitors. We 
demonstrated that TNF-a activates caspase-8, which signals apoptosis through the death 
receptor pathway, and also caspase-9, which signals apoptosis through the mitochondrial 
pathway. Thus, apoptosis was dependent on both pathways in TNF-a-stimulated 
chondrocytes. 
The generation of reactive oxygen species (ROS) in response to different external 
stimuli has been linked to the activation of transcription factors and apoptosis (Mates and 
Sanchez, 2000). Because FOXOl is activated by oxidative stress, we demonstrated a possible 
mechanism by which TNF-a might activate FOXO 1 through the generation of ROS. The 
inhibition of ROS by two independent ROS inhibitors demonstrated a decreased FOXO 1 
DNA binding at the nuclear protein level, as well as FOXOl mRNA levels in ATDC5 cells 
BMP2 stimulated (hypertrophic chondrocytes ). Our results are consistent with a previous 
report that showed that an increase in the generation of ROS enhances FOXO transcriptional 
activity (Essers et al., 2004). 
Overall, the present investigation has identified a novel function of the transcription 
factor FOXOl. For the first time, FOXOl was demonstrated to actively participate in the 
regulation of osteogenesis by promoting osteoblast differentiation, which could be observed 
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with a deacrese in RUNX2 DNA binding, alkaline phosphase activity and nodules formation 
when FOXOl was knocked down in mineralizing cultures. Thus, we suggest that when 
FOXO 1 is activated at the correct stage of the bone formation process, it promotes osteoblast 
differentiation. However, when activated at a different stage during ossification it may cause 
bone loss through an increased osteoblast apoptosis. This effect was observed during 
cytokine-induced apoptosis in MC3T3-El cells, where FOXOl knock down showed to 
diminished apoptosis. This effect can be observed in pathologies that lead to a strong host 
response with an overexpression of cytokines like periodontitis for example, where the 
production of TNF-a by macrophages, IL-1 p by macrophages and lymphocytes-T and INF-y 
by macrophages and lymphocytes-T that migrate to areas near bone during periodontal 
disease in response to inflammation induces FOXO 1 at an incorrect stage, increasing 
apoptosis of bone-lining cells and consequently decreasing new bone formation. In diseases 
like diabetes where inflammation is prolonged, a longer up-regulation of FOXO 1 induced by 
cytokines will occur. Thus, apoptosis of bone-lining cells will last longer decreasing even 
more the production of new bone (Naguib et al., 2004; Liu et al., 2006). 
FOXO 1 was also showed to be involved in the regulation of TNF-a-induced 
apoptosis, inflammation and matrix resorption in cartilage during the endochondral bone 
formation. In diseases like diabetes, an overexpression of TNF-a occurs in response to 
injuries like a fracture for example; therefore, an increase in chondrocyte apoptosis, 
osteoclastogenesis and matrix degradation takes place in the cartilage and lead to a delayed 
fracture healing. FOXO 1 as a versatile transcription factor as it is, might be used in the future 
as an important tool in the control of TNF-a overexpression. 
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